

**TITLE OF THE INVENTION: Secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 calcium channel subunit polypeptides and screening assays using same**

**5 BACKGROUND OF THE INVENTION**

Voltage-dependent  $\text{Ca}^{2+}$  channels (VDCCs) are heteromultimeric complexes present in both neuronal and non-neuronal tissues, including heart and skeletal muscle. VDCCs are minimally composed of three subunits: a pore-forming transmembrane  $\alpha_1$  subunit, a hydrophilic intracellular  $\beta$  subunit, and a membrane-associated  $\alpha_2\delta$  subunit; a transmembrane  $\gamma$  subunit is also found in skeletal muscle tissue. Multiple subtypes and/or splice variants of the  $\alpha_1$ ,  $\beta$ , and  $\alpha_2\delta$  subunits have been found.

Gabapentin ((1-aminomethyl)cyclohexane acetic acid or Neurontin) is a structural analogue of GABA, which is mainly used as an adjunctive therapy for epilepsy. Recent research suggests that gabapentin may also have clinical utility for various indications including anxiety and pain. Although designed as a lipophilic GABA-mimetic, gabapentin does not have a high affinity for either  $\text{GABA}_A$  or  $\text{GABA}_B$  receptors, GABA uptake sites, or the GABA-degrading enzyme GABA-transaminase (EC 2.6.1.19).

A novel high affinity binding site for [ $^3\text{H}$ ]gabapentin in rat, mouse, and porcine brains has been characterized. Recently, the [ $^3\text{H}$ ]gabapentin-binding protein was isolated from pig brain and identified as the  $\alpha_2\delta$ -1 subunit of VDCCs. None of the prototypic anticonvulsant drugs displace [ $^3\text{H}$ ]gabapentin binding from the  $\alpha_2\delta$ -1 subunit. [ $^3\text{H}$ ]Gabapentin-binding is stereospecifically inhibited by two enantiomers of 3-isobutyl GABA. The rank order of potency of gabapentin, and S- and R-isobutyl GABA, at the [ $^3\text{H}$ ]gabapentin binding site mirrors their anticonvulsant activity in mice. However, electrophysiological studies have yielded conflicting data on the action of gabapentin at VDCCs.

The  $\alpha_2\delta$  subunit is derived from a single gene, the product of which is extensively post-translationally modified particularly through the cleavage of the signal sequence. The polypeptide is cleaved to form disulfide-bridged  $\alpha_2$  and  $\delta$  peptides, both of which are heavily glycosylated. Although it seems clear today that the  $\alpha_2$  and  $\delta$  peptides are membrane-associated peptides, it is unclear whether these peptides comprise one or several transmembrane domains. Furthermore, the location, size and structural configuration of these eventual transmembrane domains remains to be determined.

But in any event, the fact that  $\alpha_2\delta$  is a membrane-associated protein, regardless of its precise structural configuration, renders its large scale expression in recombinant systems difficult. Indeed, as the  $\alpha_2\delta$  protein is targeted to the membrane, it requires detergent solubilisation to release it for purification. This important drawback imposes considerable

5 restrictions for any potential applications requiring large amounts of recombinant protein. Furthermore, the various subtypes of  $\alpha_2\delta$  subunits are different proteins with very low homologies. It is therefore extremely difficult to predict their respective behaviors, for example in gene truncation experiments.

10 The only assay currently available for the screening of ligands that bind the  $\alpha_2\delta$  subunit involves the use of pig membrane extracts as a source of the  $\alpha_2\delta$  subunit. Such an assay presents major inconvenients. Firstly, because the assay material is a membrane extract, it is very difficult to accurately determine the protein composition from one assay preparation to another particularly with regard to the subtype. Also, the presence of various impurities

15 in the assay preparation is a problem in small plate assays. Furthermore, as the protein preparation lacks homogeneity, the interaction between the targeted protein and the assay plate is often quite uneven. This rendres the streamlining of the assay in a high throughput format almost impossible to achieve.

20

### SUMMARY OF THE INVENTION

In the context of the present invention, the inventors have found that it was possible to delete a portion of the nucleotide sequence encoding a eukaryotic, preferably a mammal

25 cerebral cortical voltage-dependent calcium channel  $\alpha_2$  subunit to yield a soluble secreted protein which retains its affinity for [ $^3\text{H}$ ]gabapentin.

The invention concerns:

- 30 1) A purified or isolated nucleic acid encoding a mammalian secreted soluble cerebral cortical voltage-dependent calcium channel  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide.
- 2) A purified or isolated nucleic acid according to 1), comprising a polynucleotide having at least 90% identity with the sequence encoding :

- but 21*
- from amino-acid 1 to between amino-acids 1027 and 1062 of SEQ ID N°20 for  $\alpha_2\delta$ -2,
  - from amino-acid 1 to between amino-acids 984 and 1019 of SEQ ID N°22 for  $\alpha_2\delta$ -3.

3) A purified or isolated nucleic acid according to 1), having at least 90% identity with the sequence encoding :

- but 22*
- from amino-acid 1 to between amino-acids 1047 and 1062 of SEQ ID N°20 for  $\alpha_2\delta$ -2,
  - from amino-acid 1 to between amino-acids 1004 and 1019 of SEQ ID N°22 for  $\alpha_2\delta$ -3.

*but 10*

4) A purified or isolated nucleotide sequence according to 1) wherein said sequence is the sequence of SEQ ID N°1, SEQ ID N°2, SEQ ID N°3, SEQ ID N°7, SEQ ID N°8, SEQ ID N°9, SEQ ID N°13, SEQ ID N°14, SEQ ID N°15, SEQ ID N°19 or SEQ ID N°21.

*but 4*

5) A purified or isolated nucleic acid, having at least 90% identity with the nucleotide sequence of SEQ ID N°19 or SEQ ID N°21.

15

*but 5*

6) A purified or isolated polynucleotide comprising at least 10 consecutive nucleotides of the nucleotide sequence of SEQ ID N°19 or SEQ ID N°21.

*but 10*

7) A polynucleotide probe or primer hybridizing, under stringent conditions, with the with the nucleotide sequence of SEQ ID N°19 or SEQ ID N°21.

8) A method for the amplification of a nucleic acid encoding a mammalian secreted soluble cerebral cortical voltage-dependent calcium channel  $\alpha_2\delta$ -n subunit polypeptide wherein n is 2, 3 or 4, said method comprising the steps of:

- 25
- (a) contacting a test sample suspected of containing the target secreted soluble  $\alpha_2\delta$ -n subunit nucleic acid, or a sequence complementary thereto, with an amplification reaction reagent comprising a pair of amplification primers located on either side of the  $\alpha_2\delta$ -n subunit nucleic acid region to be amplified, and
  - (b) optionally, detecting the amplification products.

30

9) A kit for the amplification of a nucleic acid encoding a secreted soluble  $\alpha_2\delta$ -n subunit polypeptide wherein n is 2, 3 or 4, or a complementary sequence thereto in a test sample, wherein said kit comprises:

(a) a pair of oligonucleotide primers which can hybridize, under stringent conditions, to the secreted soluble  $\alpha_2\delta$ -n subunit nucleic acid region to be amplified;

(b) optionally, the reagents necessary for performing the amplification reaction.

5

10) A recombinant vector comprising a nucleic acid according to 1).

11) A recombinant host cell comprising a nucleic acid according to 1).

10 12) A method for producing a secreted soluble  $\alpha_2\delta$ -n subunit wherein n is 2, 3 or 4, and said method comprises the steps of:

(a) inserting the nucleic acid encoding the desired  $\alpha_2\delta$ -n subunit polypeptide in an appropriate vector;

15

(b) culturing, in an appropriate culture medium, a host cell previously transformed or transfected with the recombinant vector of step (a);

(c) harvesting the culture medium thus obtained or lyse the host cell, for example by sonication or osmotic shock;

(d) separating or purifying, from said culture medium, or from the pellet of the resultant host cell lysate, the thus produced  $\alpha_2\delta$ -n subunit polypeptide of interest.

20

13) A purified or isolated recombinant polypeptide comprising the amino acid sequence of a secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide.

25

14) A recombinant polypeptide according to 14), having at least 80% amino-acid identity with a polypeptide comprising :

- from amino acid 1 to between amino acids 1027 and 1062 of the amino acid sequence of SEQ ID N°20, or

- from amino acid 1 to between amino acids 1019 and 1079 of the amino acid sequence of SEQ ID N°22.

30

15) A recombinant polypeptide according to 14), wherein said recombinant polypeptide is selected from the group consisting of the amino acid sequences of SEQ ID n°4, SEQ ID n°5, SEQ ID n°6, SEQ ID n°10, SEQ ID n°11, SEQ ID n°12, SEQ ID n°16, SEQ ID n°17 and SEQ ID n°18.

16) A method for the screening of ligands which bind a cerebral cortical voltage-dependent calcium channel  $\alpha_2\delta$ -n subunit wherein n is 2, 3 or 4, said method comprising the steps of:

- 5       - contacting a secreted soluble recombinant calcium channel  $\alpha_2\delta$ -n subunit polypeptide with:
- a ligand of interest; and
  - a labelled compound which binds the  $\alpha_2\delta$ -n subunit; and
  - measuring the level of binding of the labelled compound to the  $\alpha_2\delta$ -n subunit.

10

17) A method according to 16), wherein said method is a scintillation proximity assay.

18) A method according to 16), wherein said method is a flashplate assay.

15 19) A method according to 16), wherein said method is a filter binding assay.

20) A method according to 16), wherein said secreted soluble recombinant calcium channel  $\alpha_2\delta$ -n subunit polypeptide is selected from polypeptides having at least 80%, preferably 90%, more preferably 95%, and most preferably 98 or 99% amino-acid identity with the polypeptide comprising from amino acid 1 to between amino-acids 984 and 1063, preferably between amino-acids 994 and 1054, and most preferably between amino-acids 1019 and 1054 of SEQ ID N°5 or SEQ ID N°16.

21) A method according to 16), wherein said secreted soluble recombinant calcium channel  $\alpha_2\delta$ -n subunit polypeptide is selected from the group consisting of SEQ ID N°6, 7, 8, 9, 13, 14 and 15, with the polypeptides of SEQ ID N°9 and SEQ ID N°15 being most preferred.

22) A kit for the screening of ligands which bind a cerebral cortical voltage-dependent calcium channel  $\alpha_2\delta$ -n subunit wherein n is 2, 3 or 4, said kit comprising:

- 30       - a secreted soluble recombinant calcium channel  $\alpha_2\delta$ -n subunit; and
- a labelled compound which binds to the  $\alpha_2\delta$ -n subunit.

Hence, the invention concerns nucleotide sequence fragments of a cerebral cortical voltage dependent calcium channel  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit cDNA encoding a soluble secreted  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide (hereinafter a  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit). Preferably, these nucleotide sequences encode a soluble secreted  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide bearing a gabapentin or a [ $^3\text{H}$ ]gabapentin binding site. More preferably, the soluble secreted  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit nucleic acid is derived from a eukaryotic, preferably a mammal, more preferably a human  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit.

10

A further object of the present invention concerns recombinant vectors comprising a nucleic acid sequence encoding a soluble secreted  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide.

15

The invention also encompasses host cells and transgenic non-human mammals comprising said nucleic acid sequences or recombinant vectors.

20

The invention also concerns a soluble secreted  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide which is characterized in that it is a soluble secreted polypeptide having affinity for [ $^3\text{H}$ ]gabapentin. Preferably, the soluble secreted polypeptide is derived from a mammal, more preferably a human  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit.

25

The inventors have also found that it was possible to use a soluble secreted form of a voltage-dependant calcium channel  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide in an assay for the screening of ligands which bind the  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit.

The invention therefore also concerns a method for the screening of ligands which bind a calcium channel  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit.

The method comprises the steps of:

30

- contacting a secreted soluble recombinant calcium channel  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide with:

- a ligand of interest; and
- a labelled compound which binds a  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit; and
- measuring the level of binding of the labelled compound to the secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit.

35

The invention also concerns a kit for the screening of ligands which bind a calcium channel  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit.

The kit comprises:

- a secreted soluble recombinant calcium channel  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide; and
- a labelled compound which binds a calcium channel  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit.

## 10 DETAILED DESCRIPTION OF THE INVENTION

The invention concerns truncated  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit cDNA sequences. These truncated sequences encode soluble secreted polypeptides which retain their affinity for [ $^3\text{H}$ ]gabapentin.

Throughout the present specification, the expression "nucleotide sequence" is used to designate indifferently a polynucleotide or a nucleic acid. More precisely, the expression "nucleotide sequence" encompasses the nucleic material and the sequence information and is not restricted to the sequence information (i.e. the succession of letters chosen among the four base letters) that biochemically characterizes a specific DNA or RNA molecule.

As used interchangeably herein, the terms "oligonucleotides", "nucleic acids" and "polynucleotides" include RNA, DNA, or RNA/DNA hybrid sequences of more than one nucleotide in either single chain or duplex form.

Further to its general meaning understood by the one skilled in the art, the term "nucleotide" is also used herein to encompass modified nucleotides which comprise at least one of the following modifications (a) an alternative linking group, (b) an analogous form of purine, (c) an analogous form of pyrimidine, or (d) an analogous sugar. For examples of analogous linking groups, purines, pyrimidines, and sugars, see for example PCT publication N<sup>o</sup>WO 95/04064.

The polynucleotide sequences of the invention may be prepared by any know method, including synthetic, recombinant, or a combination thereof as well as through any purification methods known in the art.

### A) Secreted $\alpha_2\delta$ -2, $\alpha_2\delta$ -3 or $\alpha_2\delta$ -4 subunit polypeptides

The invention comprises polynucleotide sequences encoding a soluble secreted eukaryotic, preferably a soluble secreted mammal  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide. These

sequences particularly include but are not restricted to 1) those sequences encoding a soluble secreted polypeptide of this  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit which preferably retains its binding affinity for [ $^3\text{H}$ ]gabapentin and 2) nucleotide fragments useful as nucleic acid primers or probes for amplification or detection purposes.

- 5 The expression "soluble secreted  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit" is intended to designate polypeptide sequences which, when produced by a recombinant host cell, are secreted at least partially into the culture medium rather than remaining associated with the host cell membrane.

10 **1) cDNA fragments encoding soluble secreted  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3,  $\alpha_2\delta$ -4 subunit polypeptides**

One of the important embodiments of the present invention concerns truncated nucleotide sequences of  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit cDNAs which encode soluble secreted  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptides. The inventors have found that it was possible to  
 15 generate deletion mutants of  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit cDNAs which, when expressed, produce a significant amount of soluble secreted proteins, preferably soluble secreted proteins, which retain their [ $^3\text{H}$ ]gabapentin binding affinity. These truncated nucleotide sequences of the invention are of significant value to the skilled person as they now allow fast and reliable access to significant concentrations of selected soluble secreted  $\alpha_2\delta$ -2,  
 20  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptides. To that end, the inventors have determined the minimal and optimal fragment lengths required to express a polypeptide which: 1) binds [ $^3\text{H}$ ]gabapentin with sufficient affinity and; 2) is obtained in a soluble secreted form.

The discussion provided below provides comments on possible truncations, giving as an example the human  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit. However, given the very substantial  
 25 cross-species homology for  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit sequences, the comments below can also be applied to other eukaryotic species, and more particularly other mammalian species such as rat, mouse, rabbit or pig. Their  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit sequences, which for most are available in public databases, share a very substantial homology with the human  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit sequences.

30

The inventors believe that the soluble secreted  $\alpha_2\delta$ -2 subunit polypeptides which are as close as possible to the native sequence and which are therefore more likely to retain their native folding and hence their [ $^3\text{H}$ ]gabapentin binding properties are those corresponding to the native protein in which amino-acid stretch \_\_1027\_\_ to \_\_the C-terminal end\_\_ of  
 35 the amino-acid sequence of SEQ ID N°20 has been deleted. The skilled scientist can quite easily determine within this amino-acid stretch the optimal  $\alpha_2\delta$ -2 subunit polypeptides.

The inventors also believe that the soluble secreted  $\alpha_2\delta$ -3 subunit polypeptides which are as close as possible to the native sequence and which are therefore more likely to retain



their native folding and hence their  $[^3\text{H}]$ gabapentin binding properties are those corresponding to the native protein in which amino-acid stretch 984 to C-terminal end of the amino-acid sequence of SEQ ID N°22 has been deleted. The skilled scientist can quite easily determine within this amino-acid stretch the optimal  $\alpha_2\delta$ -3 subunit polypeptides.

The invention therefore particularly concerns a nucleotide sequence encoding a polypeptide having at least 80% identity with the polypeptide comprising from amino-acid 1 to between amino-acids 1027 and 1145, preferably to between amino-acids 1062 and 1145 of SEQ ID N°20.

Preferred nucleotide sequences include those of SEQ ID N°1, SEQ ID N° 2 and SEQ ID N°3.

The invention also concerns a nucleotide sequence encoding a polypeptide having at least 80% identity with the polypeptide comprising from amino-acid 1 to between amino-acids 984 and 1085, preferably to between amino-acids 1019 and 1085 of SEQ ID N°22.

Preferred nucleotide sequences include those of SEQ ID N°7, SEQ ID N° 8 and SEQ ID N°9.

#### **B) Amplification of the soluble secreted $\alpha_2\delta$ -2, $\alpha_2\delta$ -3 or $\alpha_2\delta$ -4 subunit nucleotide sequences**

Another object of the invention consists of a method for the amplification of a nucleic acid encoding a soluble secreted  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide, preferably a polypeptide bearing a  $[^3\text{H}]$ gabapentin binding site, said method comprising the steps of:

(a) contacting a test sample suspected of containing the target  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit nucleic acid, a fragment or a variant thereof, or a sequence complementary thereto, with an amplification reaction reagent comprising a pair of amplification primers which can hybridize under stringent conditions, the  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit nucleic acid region to be amplified, and

(b) optionally, detecting the amplification products.

The expression  $[^3\text{H}]$ gabapentin binding site, when used herein is intended to designate a site which can bind either  $[^3\text{H}]$ gabapentin or other ligands such as (S+)-3-isobutyl gaba or (R-)-3-isobutyl gaba.

In a first preferred embodiment of the above method, the nucleic acid encodes a secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide of SEQ ID N°4, SEQ ID N°5, SEQ ID N°6, SEQ ID N°10, SEQ ID N°11, SEQ ID N°12, SEQ ID N°16, SEQ ID N°17 and SEQ ID N°18.

In a second preferred embodiment of the above amplification method, the amplification product is detected by hybridization with a labelled probe having a sequence which is complementary to the amplified region.

5

**C) Recombinant vectors and hosts cells for the expression of a secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide**

**1) Recombinant vectors**

10 The present invention also encompasses a family of recombinant vectors comprising any one of the nucleic acids described herein. Firstly, the invention deals with a recombinant vector comprising a nucleic acid selected from the group consisting of:

(a) a purified or isolated nucleic acid encoding a secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit having at least 80% amino acid identity with the polypeptide of SEQ ID N°20 or 22, or a sequence complementary thereto;

(b) a purified or isolated nucleic acid having at least 90% nucleotide identity with a polynucleotide selected from the group consisting of the nucleotide sequences of SEQ ID N°1, SEQ ID N°2, SEQ ID N°3, SEQ ID N°7, SEQ ID N°8, SEQ ID N°9, SEQ ID N°13, SEQ ID N°14, SEQ ID N°15 or a sequence complementary thereto;

20 (c) a purified or isolated polynucleotide comprising at least 10 consecutive nucleotides of a nucleic acid described in (a) or (b) or a sequence complementary thereto.

In a first preferred embodiment a recombinant vector of the invention is used to amplify the inserted polynucleotide of the invention in a suitable host cell, this polynucleotide 25 being amplified every time the recombinant vector replicates.

Recombinant expression vectors comprising a nucleic acid encoding secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptides that are described in the present specification are also part of the invention. These include, but are not restricted to, nucleic acids encoding from amino-acid 1 to between amino-acids 1027 and 1145, preferably between amino-acids 1062 and 1145 of SEQ ID N°20, as well as nucleic acids encoding from amino-acid 1 to between amino-acids 984 and 1085, preferably between amino-acids 1019 and 1085, of SEQ ID N°22.

Another preferred embodiment of the recombinant vectors according to the invention consist of expression vectors comprising a nucleic acid encoding  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptides of the invention, and more preferably a nucleic acid encoding a polypeptide selected from the group consisting of the amino acid sequences of SEQ ID N°4, SEQ ID N°5, SEQ ID N°6, SEQ ID N°10, SEQ ID N°11, SEQ ID N°12, SEQ ID N°16, SEQ ID N°17 and SEQ ID N°18.

Within certain embodiments, expression vectors can be employed to express the secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptides which can then be purified and for example, be used as a immunogen in order to raise specific antibodies directed against said secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptides.

- 5 Preferred eukaryotic vectors of the invention are listed hereafter as illustrative but not limitative examples: pcDNA3, pFLAG, pCMV-Script, pIND, pMC1NEO, pHIL, pGAPZA, pMT/V5-His-TOPO, pMT/V5-His, pAc5.1/V5-HisA, pDS47/V5-His, pcDNA4, pcDNA6, pEF1, pEF4, pEF6, pUB6, pZeoSV2, pRc/CMv2, pcDM8, pCR3.1, pDisplay, pSecTag2, pVP22, pEMZ, pCMV/Zeo, pSinRep5, pCEP, pREP, pHook-1

10 Preferred bacteriophage recombinant vectors of the invention are P1 bacteriophage vectors such as described by Sternberg N.L. (1992;1994).

- A suitable vector for the expression of a soluble secreted  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide is a baculovirus vector that can be propagated in insect cells and in insect cell-  
 15 lines. Specific suitable host vectors includes, but are not restricted to :pFastBac-1, pIZ/V5-His, pBacMan-1, pBlueBac4.5, pBlueBacHis2, pMelBacA, pVL1392, pVL1393

The recombinant expression vectors from the invention may also be derived from an adenovirus such as those described by Feldman and Steig. (1996) or Ohno et al. (1994).

- 20 Another preferred recombinant adenovirus according to this specific embodiment of the present invention is the human adenovirus type two or five (Ad 2 or Ad 5) or an adenovirus of animal origin (French Patent Application n°FR 93 05 954).

#### **a) Regulatory expression sequences**

- 25 Expression requires that appropriate signals are provided in the vectors, said signals including various regulatory elements such as enhancers/promoters from both viral and mammalian sources that drive expression of the genes of interest in host cells. The regulatory sequences of the expression vectors of the invention are operably linked to the nucleic acid a soluble secreted  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide.

- 30 As used herein, the term "operably linked" refers to a linkage of polynucleotide elements in a functional relationship. For instance, a promoter or an enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence.

- More precisely, two DNA molecules (such as a polynucleotide containing a promoter region and a polynucleotide encoding a desired polypeptide or polynucleotide) are said to  
 35 be "operably linked" if the nature of the linkage between the two polynucleotides does not : (1) result in the introduction of a frame-shift mutation or (2) interfere with the ability of the polynucleotide containing the promoter to direct the transcription of the coding polynucleotide.

- 40 Generally, recombinant expression vectors include origins of replication, selectable markers permitting transformation of the host cell, and a promoter derived from a highly

expressed gene to direct transcription of a downstream structural sequence. The heterologous structural sequence is assembled in an appropriate frame with the translation, initiation and termination sequences, and preferably a leader sequence capable of directing sequences of the translated protein into the periplasmic space or the extra-cellular medium.

- 5 In a specific embodiment wherein the vector is adapted for transfecting and expressing desired sequences in eukaryotic host cells, preferred vectors comprise an origin of replication from the desired host, a suitable promoter and an enhancer, and also any necessary ribosome binding sites, polyadenylation site, transcriptional termination sequences, and optionally 5'-flanking non-transcribed sequences.
- 10 DNA sequences derived from the SV 40 viral genome, for example SV 40 origin early promoter, enhancer, and polyadenylation sites may be used to provide the required non-transcribed genetic elements.

#### **b) Promoter sequences**

- 15 Suitable promoter regions used in the expression vectors according to the invention are chosen taking into account the host cell in which the heterologous nucleic acids have to be expressed.

A suitable promoter may be heterologous with respect to the nucleic acid for which it controls the expression, or alternatively can be endogenous to the native polynucleotide containing the coding sequence to be expressed.

- 20 Additionally, the promoter is generally heterologous with respect to the recombinant vector sequences within which the construct promoter/coding sequence has been inserted.

Preferred eukaryotic promoters are the CMV, polyhidran or OPIE2.

#### **c) Recombinant host cells**

25 Host cells that have been transformed or transfected with one of the nucleic acids described herein, or with one of the recombinant vector, particularly recombinant expression vector, described herein are also part of the present invention.

- Are included host cells that are transformed (prokaryotic cells) or are transfected (eukaryotic cells) with a recombinant vector such as one of those described above.
- 30 Preferred host cells used as recipients for the expression vectors of the invention are the following:

(a) prokaryotic host cells: *Escherichia coli*, strains. (i.e. DH10 Bac strain) *Bacillus subtilis*, *Salmonella typhimurium* and strains from species such as *Pseudomonas*,  
35 *Streptomyces* and *Staphylococcus*;

(b) eukaryotic host cells: HeLa cells (ATCC N°CCL2; N°CCL2.1; N°CCL2.2), Cv 1 cells (ATCC N°CCL70), COS cells (ATCC N°CRL 1650; N°CRL 1651), Sf-9 cells (ATCC N°CRL 1711), C127 cells (ATCC N°CRL-1804), 3T3 cells (ATCC N°CRL-6361),

CHO cells (ATCC N°CCL-61), human kidney 293 cells (ATCC N° 45504; N°CRL-1573), BHK (ECACC N°84100 501; N°84111301), sf 9, sf 21 and hi-5 cells.

**D) Production of recombinant secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptides**

5 The present invention also concerns a method for producing one of the amino acid sequences described herein and especially a polypeptide selected from the group consisting of the amino acid sequences of SEQ ID N°4, SEQ ID N°5, SEQ ID N°6, SEQ ID N°10, 10 SEQ ID n°11, SEQ ID n°12, SEQ ID n°16, SEQ ID n°17 or SEQ ID n°18 wherein said method comprises the steps of:

(a) inserting the nucleic acid encoding the desired amino acid sequence in an appropriate vector;

15 (b) culturing, in an appropriate culture medium, a host cell previously transformed or transfected with the recombinant vector of step (a);

(c) harvesting the culture medium thus obtained or lyse the host cell, for example by sonication or osmotic shock;

(d) separating or purifying, from said culture medium, or from the pellet of the resultant host cell lysate, the thus produced recombinant polypeptide of interest.

20 In some instances, it is required to tag the secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide prior to purification. The tag is then in most instances encoded into the nucleotide sequence that is needed to express the polypeptide. Examples of such tags include, but are not limited to sequences encoding C-myc, FLAG, a sequence of histidine residues, 25 heamagglutinin A, V5, Xpress or GST. Most of these tags can be incorporated directly into the sequence, for instance through PCR amplification by incorporating the appropriate coding sequence in one of the PCR amplification primers. However, the tag can also be introduced by other means such as covalent binding of the appropriate nucleic acid sequence encoding the tag moiety with the 3' or 5' end of the nucleic acid sequence 30 encoding the polypeptide sequence. This is the case for GST.

Purification of the recombinant secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3,  $\alpha_2\delta$ -4 subunit polypeptides according to the present invention is then carried out by passage onto a nickel or copper affinity chromatography column, such as a Ni NTA column or a Q-Sepharose column.

In another embodiment of the above method, the polypeptide thus produced is further characterized, for example by binding onto an immuno-affinity chromatography column on which polyclonal or monoclonal antibodies directed to the secreted soluble  $\alpha_2\delta$ -2 subunit polypeptide of interest have been previously immobilised.

5

In another embodiment of the invention, the secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3,  $\alpha_2\delta$ -4 subunit polypeptide can be only partially purified. For instance, it can be purified along with other contaminating proteins using an appropriate chromatography matrix such as an ion-exchange chromatography column. In such instances, it is not required to tag the desired

10

The most preferred embodiment contemplated by the inventors concerns the use of a purified tagged secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide. A particularly preferred tag is a nucleotide sequence encoding from 2 to 10, and preferably 6 histidine residues.

15

With regard to the secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide used subsequently in the screening assay of the invention, several possibilities are also open to the skilled person.

20

In a first and preferred embodiment, the secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide comprises a tag moiety which can be selected among the tags referred to above. Such tagged polypeptides are particularly useful in SPA or flashplate assays. A preferred tag is the nucleotide sequence encoding histidine residues referred to above.

25

In a second embodiment, the secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide can be used without a tag. This is the case for instance in SPA or flashplate assays comprising beads or plates coated with wheat germ lectin. In such an embodiment, the tag is not needed as the carbohydrate moieties of the secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide bind directly to the wheat germ lectin-coated beads or plates.

30

**1) Labelled compounds which bind the secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide**

In cases where the  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 binding site is the [ $^3\text{H}$ ]gabapentin binding site, the preferred labelled compound which can be used is of course gabapentin itself.

- 5 However, gabapentin is not the only labelled compound which can be used in this context. Indeed, it has been previously demonstrated that saturation binding analyses on porcine synaptic plasma cerebral cortex membranes performed in the presence of L-leucine indicate a competitive interaction of the amino acid with the [ $^3\text{H}$ ]gabapentin binding site, significantly reducing [ $^3\text{H}$ ]gabapentin binding affinity for the site. The inventors believe  
10 that this competitive interaction is true across across all the amino-acids listed in table 1 below.

15 **TABLE 1**

**Binding affinities of selected amino acids ( $\text{IC}_{50} < 500\text{nM}$ ) for the [ $^3\text{H}$ ]gabapentin site in porcine cortical membranes**

	<u>COMPOUND</u>	<u><math>\text{IC}_{50}</math> (NM) ARITHMETIC MEAN (N=3) <math>\pm</math> S.E.M.</u>
20	Gabapentin	$42.1 \pm 5.5$
	L-Norleucine	$23.6 \pm 6.7$
	L-Allo-Isoleucine	$32.8 \pm 6.0$
	L-Methionine	$49.6 \pm 10.0$
	L-Leucine	$61.3 \pm 20.9$
25	L-Isoleucine	$68.8 \pm 1.9$
	L-Valine	$330 \pm 18$
	L-Phenylalanine	$351 \pm 89$

- It is therefore possible to use commercially available labelled forms of these high affinity  
30 ligands in replacement of gabapentin. The utility of [ $^3\text{H}$ ]L-leucine has been demonstrated in a filter binding assay and in a flashplate assay format. The inventors believe that labelled amino acids but also other compounds, with affinities preferably below 500 nM in the binding assay can be used as replacements of gabapentin.

With regard to the label, several embodiments can be used in the context of the invention. Preferred labels are of course radioactive labels, a list of which is provided further in this specification.

5

## **2) Assay formats and conditions**

Several assay formats can be used to carry out the method of the present invention. Preferred assay formats include scintillation assays such as the scintillation proximity assay (SPA) or the flashplate assay. Other assay formats well known to those skilled in the arts such as the filter binding assay and the centrifugation assay are also contemplated in the present invention.

10

SPA and flashplate assays are preferred assay formats for the present invention. Additional details on these assays are provided below.

15

### **Scintillation assay format**

Scintillation assays technology either involves the use of scintillant beads (for the SPA assay) or plates (for the flashplate assay). SPA beads are usually made from either cerium-doped yttrium ion silicate ( $\text{Y}_2\text{SiO}_5\text{:Ce}$ ) or polyvinyltoluene (PVT) containing an organic scintillant such as PPO. Flashplates commonly used are those such as Ni chelate flashplates although other flashplates can also be used.

20

Assays are usually carried out in aqueous buffers using radioisotopes such as  $^3\text{H}$ ,  $^{125}\text{I}$ ,  $^{14}\text{C}$ ,  $^{35}\text{S}$  or  $^{33}\text{P}$  that emit low-energy radiation, the energy of which is easily dissipated in an aqueous environment. For example, the electrons emitted by  $^3\text{H}$  have an average energy of only 6 keV and have a very short path length ( $\sim 1\text{ }\mu\text{m}$ ) in water. If a molecule labelled with one of these isotopes is bound to the bead or flashplate surface, either directly or via interaction with another molecule previously coupled to the bead or flashplate, the emitted radiation will activate the scintillant and produce light. The amount of light produced, which is proportional to the amount of labelled molecules bound to the beads, can be measured conveniently with a liquid scintillation (LS) counter. If the labelled molecule is not attached to the bead or a flashplate surface, its radiation energy is absorbed by the surrounding aqueous solvent before it reaches the bead, and no light is produced. Thus, bound ligands give a scintillation signal, but free ligands do not, and the need for a time-consuming separation step, characteristic of conventional radioligand binding assays, is

25  
30

US 2005/0155263 A1



eliminated. The manipulations required in the assays are reduced to a few simple pipetting steps leading to better precision and reproducibility.

The conditions under which SPA and flashplate assays are performed in the context of the present invention are provided below.

5

### **Scintillation assay conditions**

#### **a) SPA assay**

The SPA assays is first developed to optimize the conditions under which the radioligand binds the secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide. The parameters  
10 which can be varied to optimize radioligand binding in a typical SPA assay using Amersham beads include assay temperature,  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide interaction with the radioligand and the SPA beads, radioligand concentration as well as pH variations.

- 15 The temperature at which the assay can be carried out can vary from 1 to 30°C. Preferred temperatures range from 18 to 23°C, with 21°C being the most preferred temperature. The interaction of the  $\alpha_2\delta$  subunit polypeptide with the SPA beads can be optimized by adjusting the concentration of the polypeptide and by introducing a reagent which will favor this interaction. When 50 mg of Amersham SPA beads are used, the  $\alpha_2\delta$ -1 subunit  
20 polypeptide concentration may vary from 0.1 to 10 pmoles per well, with the optimal concentration being generally around 5 to 6 pmoles per well.

- As for the reagent favoring the interaction between the secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide and the radioligand as well as the Amersham SPA beads, the  
25 inventors found that imidazole could be efficiently used for that purpose when the  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide is tagged with an amino acid sequence including 6 histidine residues. Furthermore, and more importantly, it was found that imidazole also enhanced binding of the radioligand to the  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 polypeptide.

- 30 The concentration of the radioligand is evaluated with respect to the concentration of secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide present in the assay medium. Generally, the concentration of radioligand varies from 1 nM to 100 nM. A preferred [ $^3\text{H}$ ]gabapentin concentration is about 5 to 20 nM, with a most preferred concentration

SECRETED: 0526260

being about 10 nM. A preferred [ $^3\text{H}$ ]leucine concentration is also about 5 to 20 nM, with a most preferred concentration being about 10 nM. It is to be noted that the concentration of other radioligands having affinities similar to those of [ $^3\text{H}$ ]gabapentin and [ $^3\text{H}$ ]leucine should also be in the range of about 5 to 20 nM.

5

Once the optimal radioligand binding conditions have been determined, a test ligand can be introduced in the assay medium to evaluate the level of displacement of the radioligand. The concentration of test ligand to be introduced in the assay medium usually varies from 0.1 nM to about 100  $\mu\text{M}$ . A preferred test ligand concentration of about 10  $\mu\text{M}$  is usually a starting point in a high throughput screening assay. Then, depending on the number of hits obtained, it may be lowered or increased.

10

It is to be noted that the parameters set forth above, which have been evaluated for a typical SPA assay using Amersham SPA beads can be adjusted by the skilled person, for example if SPA beads of a different type are used.

15

#### **b) Flashplate assay**

Similarly to the SPA assays, the flashplate can first be developed in order to optimize the conditions under which the radioligand binds the  $\alpha_2\delta$  subunit polypeptide. The parameters which can be varied to optimize radioligand binding in a typical flashplate assay using NEN Ni chelate flashplates also include assay temperature, secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide interaction with both the radioligand and the flashplates, radioligand concentration as well as pH variations.

20

The temperature at which the assay can be carried out can vary from 1 to 30°C. Preferred temperatures range from 18 to 23°C, with 21°C being the most preferred temperature.

25

The interaction of the secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide with the flashplates can be optimized by adjusting the concentration of the polypeptide and by introducing a reagent which will favor this interaction. When a standard NEN Ni chelate flashplate is used, the secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide volume usually varies between 0.5 and 20  $\mu\text{l}$  for a concentration of secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide of 0.6 pmol/ $\mu\text{l}$ . As the published maximum binding capacity of

30

2ub  
b7 NEN p plates is about 6 pmol per well, the inventors consider that an optimal concentration of secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide is probably around 5 pmol per well at 8 ul.

- 2ub  
b7
- 5 With regard to the reagent favoring the interaction between the secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide and the radioligand as well as the flashplates, the inventors believe that imidazole could also be efficiently used for that purpose when the secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide is tagged with an amino acid sequence including 6 histidine residues. The inventors also believe that imidazole concentrations can substantially enhanced binding of the radioligand to the secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 polypeptide. The optimal concentration of imidazole used to enhance radioligand binding varies depending on the concentration of secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide used in the assay. For instance, when the volume of the  $\alpha_2\delta$ -1 subunit polypeptide is about 10 ul ul ( $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 polypeptide concentration of 0.6 pmol/ul), the optimal imidazole concentration can vary between 1 and 20 mM, with a concentration of about 10 mM being preferred. As mentioned previously, other compounds such as histidine as well as pH variations may be used to enhance radioligand binding.
- 15
- 20 The concentration of the radioligand is evaluated with respect to the concentration of  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide present in the assay medium. Generally, the concentration of radioligand varies from 1 nM to 100 nM. A preferred [ $^3$ H]gabapentin concentration is about 5 to 20 nM, with a most preferred concentration being about 10 nM. A preferred [ $^3$ H]leucine concentration is also about 5 to 20 nM, with a most preferred
- 25 concentration being about 10 nM. It is to be noted that the concentration of other radioligands having affinities similar to those of [ $^3$ H]gabapentin and [ $^3$ H]leucine should also be in the range of about 5 to 20 nM.

Once the optimal radioligand binding conditions have been determined, a test ligand can be

30 introduced in the assay medium to evaluate the level of displacement of the radioligand. The concentration of test ligand to be introduced in the assay medium usually varies from 0.1 nM to about 100 uM. A preferred test ligand concentration of about 10 uM is usually a

2ub  
b7

starting point in a high throughput screening assay. Then, depending on the number of hits obtained, it may be lowered or increased.

- The inventors have tested the displacement of a particular radioligand, [ $^3\text{H}$ ]gabapentin, with (S+)-3-isobutyl gaba. The data provided in the examples which follow clearly shows that the assay can be used in high throughput competition studies.

#### **E) Purified recombinant secreted soluble $\alpha_2\delta$ -2, $\alpha_2\delta$ -3 or $\alpha_2\delta$ -4 polypeptides**

- Another object of the present invention consists of a purified or isolated recombinant polypeptide comprising the amino acid sequence of a secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide.

- Preferred isolated recombinant polypeptides of the invention include those having at least 80%, preferably 90%, more preferably 95, and most preferably 98 or 99%, amino-acid identity with polypeptides comprising from amino acid 1 to between amino-acids 1027 and 1145, preferably between amino-acids 1062 and 1145 of SEQ ID N°20, as well as those having at least 80%, preferably 90%, more preferably 95, and most preferably 98 or 99%, amino-acid identity with polypeptides comprising from amino acid 1 to between amino-acids 984 and 1085, preferably between amino-acids 1019 and 1085 of SEQ ID N°22.

- In a further preferred embodiment, the polypeptide comprises an amino acid sequence having at least 80%, preferably 90%, more preferably 95%, and most preferably 98% or 99% amino acid identity with the amino acid sequence of SEQ ID N°4, SEQ ID N°5, SEQ ID N°6, SEQ ID N°10, SEQ ID N°11, SEQ ID N°12, SEQ ID N°16, SEQ ID N°17 and SEQ ID N°19.

#### **F) Modified secreted soluble $\alpha_2\delta$ -2, $\alpha_2\delta$ -3 or $\alpha_2\delta$ -4 subunit polypeptides**

- The invention also relates to secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide comprising amino acid changes ranging from 1, 2, 3, 4, 5, 10, 20, 25, 30, 35, 40 substitutions, additions or deletions of one amino acid as regards to polypeptides of anyone of the amino acid sequences of the present invention. Preferred sequences are those of SEQ ID N°4, SEQ ID N°5, SEQ ID N°6, SEQ ID N°10, SEQ ID N°11, SEQ ID n°12, SEQ ID n°16, SEQ ID n°17 and SEQ ID N°18.

In the case of an amino acid substitution in the amino acid sequence of a polypeptide according to the invention, one or several consecutive or non-consecutive amino-acids are

replaced by "equivalent" amino-acids. The expression "equivalent" amino acid is used herein to designate any amino acid that may be substituted for one of the amino-acids belonging to the native protein structure without decreasing the binding properties of the corresponding peptides to the antibodies raised against the polypeptides of the invention.

- 5 In other words, the "equivalent" amino-acids are those which allow the generation or the synthesis of a polypeptide with a modified sequence when compared to the amino acid sequence of the secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptides of interest, said modified polypeptide being able to bind to the antibodies raised against the secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide of interest and/or to induce antibodies
- 10 recognizing the parent polypeptide.

- Alternatively, amino acid changes encompassed are those which will not abolish the biological activity of the resulting modified polypeptide. These equivalent amino-acids may be determined either by their structural homology with the initial amino-acids to be replaced, by the similarity of their net charge or of their hydrophobicity, and optionally by
- 15 the results of the cross-immunogenicity between the parent peptides and their modified counterparts.

The peptides containing one or several "equivalent" amino-acids must retain their specificity and affinity properties to the biological targets of the parent protein, as it can be assessed by a ligand binding assay or an ELISA assay.

- 20 Examples of amino-acids belonging to specific classes include Acidic (Asp, Glu), Basic (Lys, Arg, His), Non-polar (Ala, Val, Leu, Ile, Pro, Met, Phe, Trp) or uncharged Polar (Gly, Ser, Thr, Tyr, Asn, Gln) amino-acids.

- Preferably, a substitution of an amino acid in  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide of the invention, or in a peptide fragment thereof, consists in the replacement of an amino
- 25 acid of a particular class for another amino acid belonging to the same class.

By an equivalent amino acid according to the present invention is also contemplated the replacement of a residue in the L-form by a residue in the D form or the replacement of a Glutamic acid (E) residue by a Pyro-glutamic acid compound. The synthesis of peptides containing at least one residue in the D-form is, for example, described by Koch (1977).

- 30 A specific embodiment of a modified peptide of interest according to the present invention, includes, but is not limited to, a peptide molecule, which is resistant to proteolysis. This is a peptide in which the -CONH- peptide bond is modified and replaced by a (CH<sub>2</sub>NH) reduced bond, a (NHCO) retro inverso bond, a (CH<sub>2</sub>-O) methylene-oxy bond, a (CH<sub>2</sub>S) thiomethylene bond, a (CH<sub>2</sub>CH<sub>2</sub>) carba bond, a (CO-CH<sub>2</sub>) cetomethylene bond, a (CHOH-CH<sub>2</sub>) hydroxyethylene bond), a (N-N) bound, a E-alcene bond or also a -CH=CH-bond.
- 35

The invention also encompasses secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide in which at least one peptide bond has been modified as described above.

The polypeptides according to the invention may also be prepared by the conventional methods of chemical synthesis, either in a homogenous solution or in solid phase. As an illustrative embodiment of such chemical polypeptide synthesis techniques, it may be cited the homogenous solution technique described by Houbenweyl (1974).

- 5 The secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide of interest, or a fragment thereof may thus be prepared by chemical synthesis in liquid or solid phase by successive couplings of the different amino acid residues to be incorporated (from the N-terminal end to the C-terminal end in liquid phase, or from the C-terminal end to the N-terminal end in solid phase) wherein the N-terminal ends and the reactive side chains are previously
- 10 blocked by conventional groups.
- For solid phase synthesis, the technique described by Merrifield (1965a; 1965b) may be used in particular.

### **G) Antibody production**

- 15 The secreted soluble  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptides of the invention and their peptide fragments of interest can be used for the preparation of antibodies.
- Polyclonal antibodies may be prepared by immunization of a mammal, especially a mouse or a rabbit, with a polypeptide according to the invention that is combined with an adjuvant
- 20 of immunity, and then by purifying the specific antibodies contained in the serum of the immunized animal on an affinity chromatography column on which has previously been immobilized the polypeptide that has been used as the antigen.
- Monoclonal antibodies may be prepared from hybridomas according to the technique described by Kohler and Milstein (1975).
- 25 The present invention also deals with antibodies produced by the trioma technique and by the human B-cell hybridoma technique, such as described by Kozbor et al. (1983).
- Antibodies of the invention also include chimeric single chain Fv antibody fragments (US Patent N° 4,946,778; Martineau et al., (1998), antibody fragments obtained through phage display libraries Ridder et al. (1995) and humanized antibodies (Leger et al., (1997)).

### **H) Screening assays**

- 30 The invention concerns a method for the screening of ligands which bind soluble secreted  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit polypeptide. More particularly, the targeted  $\alpha_2\delta$ -2,  $\alpha_2\delta$ -3 or  $\alpha_2\delta$ -4 subunit binding site is preferably the [ $^3\text{H}$ ]gabapentin binding site. The various
- 35 parameters of the method of the invention are described in further detail below.

## EXAMPLES

### 5 Example 1

#### Construction of a nucleotide sequence encoding a soluble secreted human $\alpha_2\delta$ -2 subunit polypeptide deletion mutant of SEQ ID N°23

##### a) Primer design

10 PCR primers were designed to generate the secreted soluble human  $\alpha_2\delta$ -2 deletion mutant of SEQ ID N° 23 as follows:

5' PCR primer: This was designed to engineer in a KOZAK translation initiation consensus sequence prior to the coding sequence (Kozak *JBC* **266** 19867-19870)

15 3' PCR primer: This was designed to engineer in six histidine residues followed by a stop-codon at the desired location in the coding sequence. In addition to the stop codon the  $\alpha_2\delta$ -2 primers also included an *Eco* RI restriction site.

The bold region in each primer sequence denotes the 'tagged' region; addition of sequences not present in the template. Primers were custom synthesized by Perkin Elmer  
20 Applied Biosystems UK to the ABI ready pure grade, supplied lyophilized then resuspended to 15 $\mu$ M in 10mM TE. JB197 and 198 were provided with 5' phosphate groups:

5' Primer JB197 (5'-TCGCC**ACCATGGCGGTGCCGGCTC**-3', SEQ ID N° 25)

3' Primer JB198 (5'-TCGGAATTCCTCAGT**GATGGTGATGGGCCCGCGGCCACAGTC**-3', SEQ ID N° 28)

##### b) Protocol for PCR mediated 5' Kozak and 3' 6His tagging of human $\alpha_2\delta$ -2

30

The full length human  $\alpha_2\delta$ -2 gene (Gen Bank Accession Number AF042792) in a pcDNA 3 vector as described in Brown, J.P. and Gee, N.S., Cloning and deletion mutagenesis of the  $\alpha_2\delta$  calcium channel subunit from porcine cerebral cortex, *The journal of biological chemistry*, **273**(39):25458-25465) was used as the template in the following PCR reaction.

35 The reagents were added in the following order in triplicate to a 96 well PCR plate:

	$\mu$ l
10x Pfx Amplification buffer	5
10mM dNTPs	1.5

	50mM MgSO <sub>4</sub>	1
	15μM JB197	1.5
	15μM JB198	1.5
	100ng/μl pcDNA3.1-humans-α <sub>2</sub> δ-2	1
5	10x PCR Enhancer	5
	H <sub>2</sub> O	32.7
	2.5 UNITS/μL PFX POLYMERASE	0.8μL

The plate was the cycled on an MJ Tetrad DNA engine according to the following cycling  
10 conditions:

94°C / 2mins

*followed by:*

for 30 cycles 94°C / 45sec

15 58°C / 45sec

68°C / 4mins

*followed by:*

68°C / 10mins

*followed by:*

20 hold at 4°C

The 3366bp product was then gel purified from a 1% TAE agarose gel using QIAEX beads and eluted in approximately 50μl TE.

25

### **Example 2**

#### **Cloning of the PCR fragments of Example 1 into the Baculovirus transfer vector pFastBac1**

30 The PCR products of Example 1 were cloned into *Stu* I digested, calf intestinal phosphatase dephosphorylated, phenol chloroform extracted and QIAEX gel purified pFastBac1 (Life Technologies) using the Rapid DNA ligation kit (Roche Diagnostics) transforming XL1-blue (α<sub>2</sub>δ-1b) *E. Coli* cells:



### a) Screening for positive recombinants

- Given that the PCR product was cloned by blunt-end ligation a screen was required to select a recombinant with the gene ligated in the positive orientation with respect to the polyhedrin promoter in pFastBac1. This was achieved by restriction digest of miniprep DNA (Qiagen miniprep kit) prepared from colony minicultures and analysis on a 1% TAE agarose gel. A positive clone was identified according to the following digest patterns:

SEQ ID N° 23 in pFastBac1

Eco RI digest performed on miniprep DNA

Predicted fragments (bp)

PCR product cloned in a positive orientation

4773 and 3368

PCR product cloned in a negative orientation

8127 and 14

### 15 b) Sequencing analysis of selected clones

One positive was selected for this clone and used to prepare a plasmid DNA stock of the desired construct (QIAGEN maxi kit). Confirmatory sequence reactions were performed using the Big Dye terminator sequencing kit and run on an ABI 310 Prism Genetic Analyzer. Sequence analysis of both coding strands was performed using a selection of sequencing oligonucleotide primers.

### Example 3

#### Protocol for establishing baculovirus banks for the expression of the $\alpha_2\delta$ -2 deletion mutant SEQ ID N°23

Essentially, the protocol used to generate the baculovirus banks is that outlined in the Life Technologies Bac-to Bac™ baculovirus expression systems manual.

### a) Transposition of DH10Bac *E. coli* cells

- One ng (5µl) of the recombinant pFastBac-1 construct containing the nucleotide sequence encoding the porcine  $\alpha_2\delta$ -2 deletion mutant of SEQ ID N°23 was added to 100µl of DH10Bac cells thawed on ice. The cells were then mixed gently by tapping the tube then incubated on ice for 30 minutes before heat shock treatment by incubation in a 42°C water bath for 45 seconds. The mixture was then chilled on ice for 2 minutes before the addition of 900µl of S.O.C. medium. The mixture was then placed in a shaking incubator (200rpm) at 37°C for 4 hours. The cells were then serially diluted (10 fold dilutions from 10<sup>-1</sup> to 10<sup>-3</sup>)

and 10µl of each dilution plated on LB agar plates containing 50µg/ml kanamycin, 7µg/ml gentamicin, 10µg/ml tetracycline, 100µg/ml Blueo-gal and 40µg/ml IPTG. The plates were incubated at 37°C for between 1 and 3 days until discrete colonies of blue and white colour were discernible.

5

#### **b) Isolation of recombinant DNA**

White colonies (containing the recombinant bacmid) were picked and grown for 24 hours (to stationary phase) at 37°C with shaking (200rpm) in 2ml of LB containing 50µg/ml kanamycin, 7µg/ml gentamicin and 10µg/ml tetracycline. 1.5ml of culture was then  
 10 transferred to a microfuge tube and centrifuged at 14,000xg for 1minute. The supernatant was removed and the cells resuspended gently in 0.3ml of 15mM Tris-HCl (pH8.0), 10mM EDTA, 100µg/ml RNase A. 0.3ml of 0.2N NaOH, 1% SDS was then added and the mixture mixed gently before incubation at 22°C for 5 minutes. Then 0.3ml of 3M Potassium acetate (pH5.5) was added and the sample placed on ice for 10 minutes. After  
 15 centrifugation at 14,000xg for 10 minutes the supernatant was transferred to a tube containing 0.8ml of isopropanol, mixed then placed on ice for 10 minutes before centrifugation at 14,000xg for 10 minutes. The supernatant was then discarded and the pellet rinsed with 0.5ml of 70% ethanol before centrifugation at 14,000xg for 5 minutes. This 70% ethanol rinse was then repeated before removing all of the supernatant and air  
 20 drying the pellet for 10minutes at room temperature. The pellet was finally resuspended in 40µl of TE.

#### **c) Transfection of sf9 cells with the recombinant bacmid DNA**

A 6-well tissue culture plate was seeded with  $0.9 \times 10^6$  sf9 cells (cells at log phase having  
 25 grown from a culture passaged at  $0.3 \times 10^6$  cells/ml) per 35mm well in 2ml of Sf-900 II SFM media containing 50units/ml penicillin and 50µg/ml streptomycin. Cells were left to attach at 27°C for 1 hour. Bacmid DNA prepared as described above (5µl) was added to 200µl of Sf-900 II SFM media containing 6µl of CELLECTIN and mixed before  
 incubation at room temperature for 45 minutes. The cells were washed once with 2ml of  
 30 Sf-900 II SFM media without antibiotics then 0.8ml of Sf-900 II SFM media was added to each tube containing the lipid-DNA complex. The wash buffer was removed from the cells and the 1ml of diluted lipid-DNA complex overlaid on the cells. The cells were incubated for 5hours at 27°C after which time the transfection mixture was removed and 2ml of Sf-

900 II SFM media containing 50units/ml penicillin and 50µg/ml streptomycin was added. The cells were then incubated for 72 hours.

After incubation for 72 hours the media was removed from the cells and centrifuged at 500xg for 5 minutes. The supernatant was then transferred to a fresh tube, this was labelled as the P0 bank and stored at 4°C in the dark. The P1 bank was prepared by passaging sf9 cells at approx  $5 \times 10^6$  cells/ml to  $2 \times 10^6$  cells/ml (100ml in a 250ml Erlenmeyer flask) and adding 0.5ml of the P0 bank harvested above. The cells were then incubated shaking (200rpm) at 27°C for 4 days. Under sterile conditions the culture was centrifuged at 500xg for 10 minutes and the supernatant 0.2µM filtered (P1 bank). The P2 bank was prepared by adding 2ml of P1 bank per 400ml culture (in 1L Erlenmeyer flasks) passaged as above to  $2 \times 10^6$  cells/ml. The culture was incubated as before for 4 days and the supernatant harvested and filtered as described for the P1 bank. The supernatant was first pooled then aliquoted (10ml) and stored at 4°C.

15

**Example 4**  
**Expression of the  $\alpha_2\delta$ -2 deletion mutant of SEQ ID N°23**

To sf9 cells passaged from  $\sim 5 \times 10^6$  cells/ml to  $2 \times 10^6$  cells/ml in Sf-900 II SFM media was added 0.1ml virus per 100ml of cells of the appropriate viral bank (400ml volumes in 1L Erlenmeyer flasks). The cells were then cultured for 4-5 days at 27°C with 110rpm shaking. Expression of the protein was confirmed by SDS-PAGE and Western blotting using an anti penta-His monoclonal antibody (Qiagen) and was detected in the culture supernatant and cell lysate.

25

**Example 5**  
**Purification of  $\alpha_2\delta$ -2 deletion mutant of SEQ ID N°23**

The  $\alpha_2\delta$ -2 deletion mutant of SEQ ID N°23 was purified from the cell lysate following the purification strategy outlined below:

30

The culture was centrifuged at 6,000xg for 10 minutes and the supernatant removed. The weight of the cell pellet was determined before re-suspension in 20mM Tris pH8.0, 100mMKCl, 1% P40-Nonidet (100ml per 20g of wet cells). A protease inhibitor cocktail

(Sigma, Cat# P8849), 1ml/L, was added to the mixture. The solution was then stirred for 10 minutes before centrifugation for 1 hour at 30,000xg and 4°C. The supernatant was concentrated (30kDa cut off) to approx. ~300ml then centrifuged for 1 hour at 100,000xg.

- 5 Supernatant containing the soluble proteins was diluted 1:3 in 10mM Tris-HCl pH8.0 (equilibration buffer) and loaded onto a pre-equilibrated Q-Sepharose column (2.5cm i.d. x 30cm h.) at a flow rate of 900ml/h. After washing with equilibration buffer until a stable  $A_{280nm}$  baseline had been achieved, protein was eluted with 20mM Tris-HCl pH8.0, 0.5M KCl, 10mM Imidazole.

10

The eluate was then loaded onto a Ni-NTA (Qiagen) column (2.5cm i.d. x 6cm h.) pre-equilibrated in 20mM Tris pH8.0, 0.5M KCl, 10mM Imidazole at a flow rate of 2 ml/min.

The column was washed successively with buffer A (20mM Tris pH8.0, 0.5M KCl, 20mM Imidazole), buffer B (100mM Tris-HCl pH8.0, 1M KCl), and buffer A again. Elution was performed with buffer C (20mM Tris-HCl pH8.0, 100mM KCl, 0.5M Imidazole). The Ni-NTA eluate (~50ml) was concentrated (30kDa cut-off) to ~2ml and applied at 1ml/min and in 0.2ml aliquots, to an FPLC Superdex-200 column equilibrated in 10mM HEPES, pH7.4, 150mM NaCl. Fractions containing the polypeptide of SEQ ID N°23 were pulled.

20

#### Example 6

#### SPA assay of [ $^3$ H]gabapentin binding to the secreted soluble human $\alpha_2\delta$ -2 subunit of SEQ ID N°23

- 25 The assay is carried out at 21°C. Assay components are added in the following order (all reagents are diluted in 10mM HEPES (pH 7.4 at 21°C) to 96-well Optiplates:

25µl imidazole at various concentrations (diluted from a 1M stock pH8.0, see assay details)

50µl 10mM HEPES pH 7.4

30

25µl (50mg) SPA beads (Amersham)

100µl s- $\alpha_2\delta$ -2 subunit polypeptide of SEQ ID No 23 (2µl protein

diluted to 100µl)

25µl radioligand ([ $^3$ H]gabapentin obtained from example 5

- Immediately after adding radioligand, the optiplates were loaded in the Packard Top Count scintillation counter to follow the binding time course. Imidazole was first used in the assay to optimize the specific interaction of the protein's 6His tag with the SPA bead. Imidazole itself (up to 100mM) in the filtration assay has no effect on [<sup>3</sup>H]gabapentin binding (n=1).

#### Example 7

#### Ni Flashplate assay of [<sup>3</sup>H]gabapentin binding to secreted soluble human $\alpha_2\delta$ -2 (SEQ ID N°23)

- 10 Assays are carried out at 21°C in a final volume of 250µl in 96-well NEN Ni chelate flash plates. Assay components are added in the following order (all reagents were diluted in 10mM HEPES (pH 7.4 at 21°C)):

25µl 10mM HEPES pH7.4

25µl imidazole at various concentrations (diluted from a 1M stock pH8.0, see assay details)

75µl 10mM HEPES pH 7.4

100µl s- $\alpha_2\delta$ -2-6His (2µl protein diluted to 100µl) obtained from example 5

25µl radioligand ([<sup>3</sup>H]gabapentin (65Ci/mmol))

Immediately after adding the radioligand, flash plates are loaded in the Packard Top Count scintillation counter to follow the binding time course. The '[<sup>3</sup>H] flash plate' programme (cpm) is used to monitor activity. Imidazole is first used in the assay to optimize the specific interaction of the protein's 6His tag with the Ni flashplate.

#### Example 8

#### Ni Flashplate assay of [<sup>3</sup>H]Leucine binding to secreted soluble human $\alpha_2\delta$ -2-6His

- 30 The procedure described in example 7 is repeated, except that [<sup>3</sup>H]gabapentin is replaced by 25 ul (10.1 nM) of [<sup>3</sup>H]Leucine (141 Ci/mmol).

### Example 9

~~Ni Flashplate assay studying competitive binding of [<sup>3</sup>H]gabapentin and (S+)-3-isobutyl GABA to human  $\alpha_2\delta$ -2-6His (SEQ ID N°23).~~

- 5 Assays are carried out at 21°C in a final volume of 250µl in 96-well NEN Ni chelate flash plates. Wells are set up for both 'total' and 'non-specific' binding. Specific binding is defined as that remaining after subtraction of the average of the 'non-specific binding' values from the average of the 'total' binding values. Assay components are added in the following order (all reagents were diluted in 10mM HEPES (pH 7.4 at 21°C)):
- 10 *out B12* 25µl 10mM HEPES pH 7.4 or 25 ul othe test compound at the appropriate concentration in HEPES
- 25µl 200 mM imidazole (diluted from a 1M stock pH8.0, see assay details)
- Total binding 75µl 10mM HEPES pH 7.4
- 15 Non-specific binding 50µl 10mM HEPES pH 7.4 and 25µl 100µM (S+)-3-isobutyl GABA
- 100µl α<sub>2</sub>δ-2-6His (2µl protein\* diluted to 100µl)
- 25µl radioligand ([<sup>3</sup>H]gabapentin or [<sup>3</sup>H]Leucine)
- 20 \* The source of α<sub>2</sub>δ-2-6His is that purified by fplc Superdex-200 gel filtration (see example 5)
- Immediately after adding radioligand, flash plates are loaded in the Packard Top Count scintillation counter to follow the binding time course. Incubation time before the assay is 3 hours. The '[<sup>3</sup>H] flash plate' programme (cpm) is used to monitor activity
- 25 Competition studies are compared across the flash-plate and filter binding methodologies in order to validate the new assay technology with the established filter binding methodology.
- GraphPad Prism software is used to process competition curve data and determine IC<sub>50</sub> and
- 30 hill slope values. Twelve point competition curves with half log dilution steps of test compounds are used in the experiments.

**Example 10****Filter binding assay of [<sup>3</sup>H]gabapentin binding to the recombinant polypeptide of SEQ ID N°23**

- 5 Assays were carried out at 21°C in a final volume of 250µl in 96-deep well plates. Assay components were (all reagents were diluted in 10mM HEPES (pH 7.4 at 21°C)):

25µl compound to test

200µl Polypeptide of SEQ ID N°23 (3µl protein diluted to 200µl)

25µl radioligand ([<sup>3</sup>H]gabapentin (65Ci/mmole))

10

Plates were incubated at room temperature for 1h prior to filtering on to 96-well GF/B Unifilter plates pre-soaked in 0.3% polyethylenimine. Filters were washed with 3x1ml 50mM Tris-HCl (pH 7.4 at 4°C), and dried over-night. Scintillant (Microscint O, 50µl) was added and the plates counted using a Packard Top Count scintillation counter. Specific binding was ~98% of the 'total' value. In [<sup>3</sup>H]gabapentin saturation studies, the K<sub>D</sub> (nM) obtained was about 10.62. Table 2 below provides the results of the competition studies.

15

**Example 11****Construction of a nucleotide sequence encoding a soluble secreted mouse α<sub>2</sub>δ-3 deletion mutant of SEQ ID N°25 as follows.**

20

**a) Primer design**

PCR primers were designed to generate the secreted soluble mouse α<sub>2</sub>δ-3 deletion mutant of SEQ ID N° 25 as follows:

25

5' PCR primer: This was designed to engineer in a KOZAK translation initiation consensus sequence prior to the coding sequence (Kozak *JBC* **266** 19867-19870)

3' PCR primer: This was designed to engineer in six histidine residues followed by a stop-codon at the desired location in the coding sequence. In addition to the stop codon the α<sub>2</sub>δ-

30

3 primers also included an *Eco* RI restriction site.

The bold region in each primer sequence denotes the 'tagged' region; addition of sequences not present in the template. Primers were custom synthesized by Perkin Elmer Applied Biosystems UK to the ABI ready pure grade, supplied lyophilized then

resuspended to 15 $\mu$ M in 10mM TE. JB201 and 202 were provided with 5' phosphate groups:

5' Primer JB201 (5'-TCGCCACCATGGCCGGGCGGGC-3', SEQ ID N°27)

3' Primer JB202 (5'-TCTCAGTGATGGTGATGGTGATGCGATGCACCCCCACACTCTC-3', SEQ ID N°28)

**b) Protocol for PCR mediated 5' Kozak and 3' 6His tagging of mouse  $\alpha_2\delta$ -3**

- 10 The full length mouse  $\alpha_2\delta$ -3 gene (Gen Bank Accession number AJ010949) in the pcDNA3 vector as described in Brown, J.P. and Gee, N.S., Cloning and deletion mutagenesis of the  $\alpha_2\delta$  calcium channel subunit from porcine cerebral cortex, *The journal of biological chemistry*, **273**(39):25458-25465) was used as the template in the following PCR reaction.

15

*The reagents were added in the following order in triplicate to a 96 well PCR plate:*

	$\mu$ l
10x Pfx Amplification buffer	5
10mM dNTPs	1.5
20 50mM MgSO <sub>4</sub>	1
15 $\mu$ M JB201	1.5
15 $\mu$ M JB202	1.5
100ng/ $\mu$ l pcDNA3-mouse- $\alpha_2\delta$ -3	1
10x PCR Enhancer	5
25 H <sub>2</sub> O	32.7
2.5 UNITS/ $\mu$ L PFX POLYMERASE	0.8 $\mu$ L

The plate was the cycled on an MJ Tetrad DNA engine according to the following cycling conditions:

30

94°C / 2mins

*followed by:*

for 30 cycles 94°C / 45sec

60°C / 45sec



68°C / 4mins

*followed by:*

68°C / 10mins

*followed by:*

5 hold at 4°C

The 3244bp product was then gel purified from a 1% TAE agarose gel using QIAEX beads and eluted in approximately 50µl.

The truncated protein of SEQ ID N°24 was expressed such the procedure of example 2,3  
10 and 4.

## **REFERENCES**

- Perez-Reyes, E., and Schneider, T. (1994) *Drug Dev. Res.* **33**, 295-318
- Catterall, W. A. (1995) *Annu. Rev. Biochem.* **64**, 493-531
- 15 - Birnbaumer, L., Campbell, K. P., Catterall, W. A., Harpold, M. M., Hofmann, F., Horne, W. A., Mori, Y., Schwartz, A., Snutch, T. P., Tanabe, T., and Tsien, R. W. (1994) *Neuron* **13**, 505-506
- Brust, P. F., Simerson, S., McCue, A. F., Deal, C. R., Schoonmaker, S., Williams, M. E., Velicelebi, G., Johnson, E. C., Harpold, M. M., and Ellis, S. B. (1993)
- 20 *Neuropharmacology* **32**, 1089-1102
- Itagaki, K., Koch, W. J., Bodi, L., Klockner, U., Sligh, D. F., and Schwartz, A. (1992) *FEBS Lett.* **297**, 221-225
- Mikami, A., Imoto, F., Tanabe, T., Niidome, T., Mori, Y., Takeshima, H., Narumiya, S., and Numa, S. (1989) *Nature* **340**, 230-233
- 25 - Mori, Y., Friedrich, T., Kim, M. S., Mikami, A., Nakai, J., Ruth, P., Bosse, E., Hofmann, F., Flockerzi, V., Furuichi, T., Mikoshiba, K., Imoto, K., Tanabe, T., and Numa, S. (1991) *Nature* **350**, 398-402
- Singer, D., Biel, M., Lotan, I., Flockerzi, V., Hofmann, F., and Dascal, N. (1991) *Science* **253**, 1553-1657
- 30 - Ramsay, R. E. (1994) *Neurology* **44**, Suppl. 5, 23-30
- Watson, W. P., and Little, H. J. (1995) *Br. J. Pharmacol.* **116**, 33P (abstr.)
- Singh, L., Field, M. J., Ferris, P., Hunter, J. C., Oles, R. J., Williams, R. G., and Woodruff, G. N. (1996) *Psychopharmacology* **127**, 1-9
- Xiao, W. H., and Bennet, G. L. (1995) *Soc. Neurosci.* **21**, 897 (abstr.)
- 35 - Mellick, G. A., Mellicy, L. B., and Mellick, L. B. (1995) *J. Pain Symptom Manage.* **10**, 265-266



- Brickley, K., Campbell, V., Berrow, N., Leach, R., Norman, R. I., Wray, D., Dolphin, A. C., and Baldwin, S. A- (1995) *FEBS Lett.* **364**,129-133
- Brice, N. L., Berrow, N. S., Campbell, V., Page, K. M., Brickley, K., Tedder, I., Dolphin, A C. (1997) *Eur. J. Neurosci.* **9**, 749-759
- 5 - Wiser, O., Trus, M., Tobi, D., Halevi, S., Giladi, E., and Atlas, D. (1996) *FEBS Lett.* **379**,15-20
- Xu, X., and Arnason, U. (1994) *Gene (Amst.)* **148**, 357-362
- Williams, M. E., Feldman, D. H., McCue, A. F., Brenner, R., Velicelebi, G., Ellis, S. B., and Harpold, M. M. (1992) *Neuron* **8**, 71-84
- 10 - Kim, H. L., Kim, H., Lee, P., King, R. G., and Chin, H. (1992) *Proc. Natl. Acad. Sci. U.S.A.* **89**,3251-3255
- Brown, J. P., Dissanayake, V. U. K., Briggs, A. R., Milic, M. R., and Gee, N. S. (1998) *Anal. Biochem.* **255**, 236-243
- Higuchi, R. (1990) in *PCR Protocols: A Guide to Methods and Applications* (Innis, M. A., Gelfand, D. H., Sninsky, J. J., and White, T. J. eds) pp. 177-183, Academic Press, Ltd., London
- 15 - Bradford, M. M. (1976) *Anal. Biochem.* **72**, 248-252
- Kyte, J., and Doolittle, F. (1982) *J. Mol. Biol.* **157**, 105-132
- Summers, M. F., Henderson, L. E., Chance, M. R., Bess, J. W., Jr., South, T. L., Blake, P. R., Sagi, I., Perez-Alvarado, G., Sowder, R. C., Hare, D. R., and Arthur, L. O. (1992) *Protein Sci.* **1**, 563-574
- 20 - Klug, A. and Rhodes, D. (1987) *Trends. Biochem. Sci.* **12**, 464-469
- Pieler, T., and Bellefroid, E. (1994) *Mol. Biol. Rep.* **20**, 1-8
- Preston, R. A., Manolson, M. F., Becherer, M, Weidenhammer, E., Kirkpatrick, D., Wright, R., and Jones, E. W. (1991) *Mol. Cell, Biol.* **11**, 5801-5812
- 25 - Tan, X., Waterham, H. R., Veenhuis, M., and Cregg, J. M. (1995) *J. Cell Biol.* **128**,307-319
- Scotland, P. B., Colledge, M., Melnikova, I., Dai, Z., and Froehner, S. C. (1993) *J. Cell Biol.* **123**, 719-728
- 30 - Henderson, L. E., Copeland, T. D., Sowder, R. C., Smythers, G. W., and Oroszlan, S. (1981) *J. Biol. Chem.* **256**, 8400- 8406
- Beaucauge et al., *Tetrahedron Lett* (1981) **22**: 1859-1862.
- Brown El., Belagaje R, Ryan MJ, Khorana HG, *Methods Enzymol* (1979); **68**, 109-151.
- Feldman and Steg, (1996) *Medecine/Sciences, synthese*, **12**, 47-55.
- 35 - Houbenweyl, (1974), in *Meuthode der Organischen Chemie*, E. Wunsch Ed., Volume 15-I et 15-II, Thieme, Stuttgart.
- Koch Y. (1977), *Biochem. Biophys. Res. Commun.*, **74**, 488-491.
- Kohler G. and Milstein C., (1975) *Nature*, **256**, 495.

- Kozbor et al., (1983) *Hybridoma*, **2**(1), 7-16.
- Leger OJ, et al. (1997) *Hum Antibodies* , **8**(1), 3-16.
- Martineau P, Jones P, Winter G. (1998), *J. Mol Biol*, **280**(1), 117-127.
- Merrifield RB, 1965a, *Nature*, **207**(996), 522-523.
- 5 - Merrifield RB, 1965b, *Nature*, **207** (996), 22-523.
- Narang SA, Hsiung HM, Brousseau R, *Methods Enzymol* 1979, **68**, 90-98.
- Ohno et al., (1994), *Science*, **265**, 781-784.
- O'Reilly et al., (1992) *Baculovirus expression vectors: a Laboratory Manual*. W.H. Freeman and Co., New York.
- 10 - Ridder R. Schmitz R, Legay F, Gram H, (1995) *Biotechnology* (NY), **13**(3), 255-260.
- Smith et al., (1983), *Mol. Cell. Biol.*, **3**, 2156-2165.
- Sternberg N.L. (1992), *Trends Genet*, **8**, 1-16.
- Sternberg N.L. (1994) *Mamm. Genome*, **5**, 397-404.
- Sambrook, J. Fritsch, E.F. and T. Maniatis (1989). *Molecular cloning: a laboratory*
- 15 *manual*, 2ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
- Sanchez-Pescador R., (1988), *J. Clin. Microbiol.*, **26**(10), 1934-1938.
- Urdea et al., MS (1988) *Nucleic Acids Research*, **11**, 4937-4957.
- Urdea et al., MS (1991) *Nucleic Acids Symp Ser.*, **24**, 197-200.

SEQUENCE LISTING**1 - human nucleotide sequence**

ATGGCGGTGCCGGCTCGGACCTGCGGCGCCTCTCGGCCCCGGCCCAGCGCGGACTGCGCGCC  
 5 CCTGGCCCCGGCTGCGGCCCCCACCCTGGCCCCGGCACC CGCGCCCCGACGTCCGGGCCCCC  
 GCGCCCCGCTGTGGCTGCTGC&TGCCGCTTCTACCGCTGCTCGCCGCCCCCGGCGCCTCTGC  
 CTACAGCTTCCCCCAGCAGCACACGATGCAGCACTGGGCCCCGGCGTCTGGAGCAGGAGGTC  
 GACGGCGTGATGCGGATTTTTTGGAGGCGTCCAGCAGCTCCGTGAGATTTACAAGGACAACC  
 GGAACCTGTTTCGAGGTACAGGAGAATGAGCCTCAGAAGTTGGTGGAGAAGGTGGCAGGGGA  
 10 CATTGAGAGCCTTCTGGACAGGAAGGTGCAGGCCCTGAAGAGACTGGCTGATGCTGCAGAG  
 AACTTCCAGAAAGCACACCGCTGGCAGGACAACATCAAGGAGGAAGACATCGTGACTATG  
 ACGCCAAGGCTGACGCTGAGCTGGACGACCCTGAGAGTGAGGATGTGGAAGGGGGTCTAA  
 GGCCAGCACCCTAAGGCTGGACTTCATCGAGGACCCAAACTTCAAGAACAAGGTCAACTAT  
 TCATACGCGGCTGTACAGATCCCTACGGACATCTACAAAGGCTCCACTGTCATCCTCAATG  
 15 AGCTCAACTGGACAGAGGCCCTGGAGAATGTGTTTCATGGAAAACCGCAGACAAGACCCAC  
 ACTGCTGTGGCAGGTCTTCGGCAGCGCCACAGGAGTCACTCGCTACTACCCGGCCACCCCG  
 TGGCGAGCCCCCAAGAAGATCGACCTGTACGATGTCCGAAGGAGACCCTGGTATATCCAGG  
 GGGCCTCGTCACCCAAAGACATGGTCATCATCGTGGATGTGAGTGGCAGTGTGAGCGGCCT  
 GACCCTGAAGCTGATGAAGACATCTGTCTGCGAGATGCTGGACACGCTGTCTGATGATGAC  
 20 TATGTGAATGTGGCCTCGTTCAACGAGAAGGCACAGCCTGTGTATGCTTCACACACCTGG  
 TGCAGGCCAATGTGCGCAACAAGAAGGTGTTCAAGGAAGCTGTGCAGGGCATGGTGGCCAA  
 GGGCACACAGGCTACAAGGCCGGCTTTGAGTATGCCTTTGACCAGCTGCAGAACTCCAAC  
 ATCACTCGGGCCAACTGCAACAAGATGATCATGATGTTACGGATGGTGGTGAGGACCGCG  
 TGCAGGACGTCTTTGAGAAGTACAATTGGCCAAACCGGACGGTGCGCGTGTTTACTTTCTC  
 25 CGTGGGGCAGCATAACTATGACGTCAACCGCTGCAGTGGATGGCCTGTGCCAACAAAGGC  
 TACTATTTTGAGATCCCTTCCATCGGAGCCATCCGCATCAACACACAGGAATATCTAGATG  
 TGTTGGGCAGGCCCATGGTGCTGGCAGGCAAGGAGGCCAAGCAGGTTCACTGGACCAACGT  
 GTATGAGGATGCACTGGGACTGGGGTTGGTGGTAACAGGGACCCTCCCTGTTTTTCAACCTG  
 ACACAGGATGGCCCTGGGGAAAAGAAGAACAGCTGATCCTGGGCGTGATGGGCATTGACG  
 30 TGGCTCTGAATGACATCAAGAGGCTGACCCCCAACTACACGCTTGGAGCCAACGGCTATGT  
 GTTTGCCATTGACCTGAACGGCTACGTGTTGCTGCACCCCAATCTCAAGCCCCAGACCACC  
 AACTTCCGGGAGCCTGTGACTCTGGACTTCTTGATGCGGAGCTAGAGGATGAGAACAAGG  
 AAGAGATCCGTCGGAGCATGATTGATGGCAACAAGGGCCACAAGCAGATCAGAACGTTGGT  
 CAAGTCCCTGGATGAGAGGTACATAGATGAGGTGACACGGAACTACACCTGGGTGCCTATA  
 35 AGGAGCACTAACTACAGCCTGGGGCTGGTGCTCCCAACCTACAGCACCTTCTACCTCCAAG  
 CCAATCTCAGTGACCAGATCCTGCAGGTCAAGTATTTTGGAGTTCCTGCTCCCAGCAGCTT  
 TGAGTCTGAAGGACACGTTTTTCATTGCTCCAGAGAGTACTGCAAGGACCTGAATGCCTCA  
 GACAACAACACCGAGTTCTTGAAAACTTTATTGAGCTCATGGAGAAAGTGACTCCAGACT  
 CCAAGCAGTGCAACAACCTTCTTCTGCACAACCTGATCTTGGACACGGGCATCACGCAGCA

5

## 20

25

30

35

TCACTCGGGCCAACTGCAACAAGATGATCATGATGTTTACGGATGGTGGTGAGGACCGCGT  
 GCAGGACGTCTTTGAGAAGTACAATTGGCCAAACCGGACGGTGCGCGTGTTTACTTTCTCC  
 GTGGGGCAGCATAACTATGACGTCACACCGCTGCAGTGGATGGCCTGTGCCAAACAAAGGCT  
 ACTATTTTGAGATCCC'TTCCATCGGAGCCATCCGCATCAACACACAGGAATATCTAGATGT  
 5 GTTGGGCAGGCCCATGGTGCTGGCAGGCAAGGAGGCCAAGCAGGTTTCACTGGACCAACGTG  
 TATGAGGATGCACTGGGACTGGGGTTGGTGGTAACAGGGACCCTCCCTGTTTTCAACCTGA  
 CACAGGATGGCCC'TGGGAAAAGAAGAACAGCTGATCCTGGGCGTGATGGGCATTGACGT  
 GGCTCTGAATGACATCAAGAGGCTGACCCCCAAC'TACACGCTTGGAGCCAACGGCTATGTG  
 TTTGCCATTGACCTGAACGGCTACGTGTTGCTGCACCCCAATCTCAAGCCCCAGACCACCA  
 10 ACTTCCGGGAGCCTGTGACTCTGGACTTCC'TGGATGCGGAGCTAGAGGATGAGAACAAGGA  
 AGAGATCCGTCGGAGCATGATTGATGGCAACAAGGGCCACAAGCAGATCAGAACGTTGGTC  
 AAGTCCCTGGATGAGAGGTACATAGATGAGGTGACACGGAAC'TACACCTGGGTGCC'TATAA  
 GGAGCACTAACTACAGCCTGGGGCTGGTGCTCCACCC'TACAGCACCTTCTACCTCCAAGC  
 CAATCTCAGTGACCAGATCCTGCAGGTCAAGTATTTTGAGTTCTTGCTCCCCAGCAGCTTT  
 15 GAGTCTGAAGGACACGTTTTCATTGCTCCCAGAGAGTACTGCAAGGACCTGAATGCCTCAG  
 ACAACAACACCGAGTTCTTGAAAACTTTTATTGAGCTCATGGAGAAAGTGACTCCAGACTC  
 CAAGCAGTGCAACAAC'TTCTTCTGCACAACCTGATCTTGGACACGGGCATCACGCAGCAG  
 CTGGTAGAGCGTGTGTGGAGGGACCAGGATCTCAACACGTACAGCCTACTGGCCGTGTTTCG  
 CTGCCACAGACGGTGGCATCACCCGAGTCTTCCCCAACCAAGGCAGCTGAGGACTGGACAGA  
 20 GAACCCTGAGCCCTTCAATGCCAGCTTCTACCGCCGCAGCCTGGATAACCACGGTTATGTC  
 TTCAAGCCCCCACACCAGGATGCCCTGTTAAGGCCGCTGGAGCTGGAGAATGACACTGTGG  
 GCATCCTCGTCAGCACAGCTGTGGAGCTCAGCCTAGGCAGGCGCACACTGAGGCCAGCAGT  
 GGTGGGCGTCAAGCTGGACCTAGAGGCTTGGGCTGAGAAGTTCAAGGTGCTAGCCAGCAAC  
 CGTACCCACCAAGACCAGCCTCAGAAGTGGCGCCCCAACAGCCACTGTGAGATGGACTGCG  
 25 AGGTTAACAATGAGGACTTACTCTGTGTCTCTATTGATGATGGAGGATTCTTGGTGTGTCTC  
 AAACCAGAACCATCAGTGGGACCAGGTGGGCAGGTTCTTTCAGTGAGGTGGATGCCAACCTG  
 ATGCTGGCACTCTACAATAACTCTTCTACACCCGCAAGGAGTCTTATGACTATCAGGCAG  
 CCTGTGCCCCCTCAGCCCCCTGGCAACCTGGGTGCTGCACCCCGGGGTGTCTTTGTGCCAC  
 CGTTGCAGATTTCTTAACTTGGCCTGGTGGACCTCTGCTGCCGCCCTGGTCCCTGTTCCAG  
 30 CAGCTTCTCTACGGCCTCATCTACCACAGCTGGTTCCAAGCAGACCCCGCGGAGGCCGAGG  
 GGAGCCCCGAGACGCGCGAGAGCAGCTGCGTCATGAAACAGACCCAGTACTACTTCCGGCTC  
 GGTAAACGCCTCTACAACGCCATCATCGACTGCGGAAACTGCTCCAGGCTGTTCCACGCG  
 CAGAGACTGACCAACACCAATCTTCTCTTTGTGGTGGCCGAGAAGCCGCTGTGCAGCCAGT  
 GCGAGGCTGGCCGGCTGCTGCAGAAGGAGACGCAC'TGCCAGCGGACGGCCCGGAGCAGTG  
 35 TGAGCTAGTGACAG

00307550 001600  
 00307550 001600

## 3 - human nucleotide sequence

ATGGCGGTGCCGGCTCGGACCTGCGGCGCCTCTCGGCCCCGGCCCAGCGCGGACTGCGCGCC  
 CCTGGCCCCGGCTGCGGCCCCCACCCTGGCCCCGGCAGCCGGCGCCCCGACGTCCGGGCCCCC  
 GCGCCCGCTGTGGCTGCTGCTGCCGCTTCTACCGTGCTCGCCGCCCCCGGCGCCTCTGCC  
 5 TACAGCTTCCCCCAGCAGCACACGATGCAGCACTGGGCCCCGGCGTCTGGAGCAGGAGGTCTG  
 ACGGCGTGATGCGGATTTTTTGGAGGCGTCCAGCAGCTCCGTGAGATTTACAAGGACAACCG  
 GAACCTGTTTCGAGGTACAGGAGAATGAGCCTCAGAAGTTGGTGGAGAAGGTGGCAGGGGAC  
 ATTGAGAGCCTTCTGGACAGGAAGGTGCAGGCCCTGAAGAGACTGGCTGATGCTGCAGAGA  
 ACTTCCAGAAAGCACACCGCTGGCAGGACAACATCAAGGAGGAAGACATCGTGTACTATGA  
 10 CGCCAAGGCTGACGCTGAGCTGGACGACCCTGAGAGTGAGGATGTGGAAAGGGGGTCTAAG  
 GCCAGCACCTAAGGCTGGACTTCATCGAGGACCCAACTTCAAGAACAAGGTCAACTATT  
 CATACGCGGCTGTACAGATCCCTACGGACATCTACAAAGGCTCCACTGTCATCTCAATGA  
 GCTCAACTGGACAGAGGCCCTGGAGAATGTGTTTCATGGAAAACCGCAGACAAGACCCACACA  
 CTGCTGTGGCAGGTCTTCGGCAGCGCCACAGGAGTCACTCGCTACTACCCGGCCACCCCGT  
 15 GGCGAGCCCCCAAGAAGATCGACCTGTACGATGTCCGAAGGAGACCCCTGGTATATCCAGGG  
 GGCCTCGTCACCCAAAGACATGGTCATCATCGTGGATGTGAGTGGCAGTGTGAGCGGCCTG  
 ACCCTGAAGCTGATGAAGACATCTGTCTGCGAGATGCTGGACACGCTGTCTGATGATGACT  
 ATGTGAATGTGGCCTCGTTCAACGAGAAGGCACAGCCTGTGTTCATGCTTCACACACCTGGT  
 GCAGGCCAATGTGCGCAACAAGAAGGTGTTCAAGGAAGCTGTGCAGGGCATGGTGGCCAAG  
 20 GGCACCACAGGCTACAAGGCCGGCTTTGAGTATGCCTTTGACCAGCTGCAGAACTCCAACA  
 TCACTCGGGCCAAGTGAACAAGATGATCATGATGTTTACGGATGGTGGTGGAGACCGCGT  
 GCAGGACGTCTTTGAGAAGTACAATTGGCCAAACCGACGGTGCGCGTGTCTTACTTTCTCC  
 GTGGGGCAGCATAACTATGACGTACACCCGTGCGAGTGGATGGCCTGTGCCAACAAAGGCT  
 ACTATTTTGGAGATCCCTTCCATCGGAGCCATCCGCATCAACACACAGGAATATCTAGATGT  
 25 GTTGGGCAGGCCCATGGTGCTGGCAGGCAAGGAGGCCAAGCAGGTTTCAAGTGGACCAACGTG  
 TATGAGGATGCACTGGGACTGGGGTTGGTGGTAACAGGGACCCTCCCTGTTTTTCAACCTGA  
 CACAGGATGGCCCTGGGGAAAAGAAGAACCAGCTGATCCTGGGCGTGATGGGCATTGACGT  
 GGCTCTGAATGACATCAAGAGGCTGACCCCCAACTACACGCTTGGAGCCAACGGCTATGTG  
 TTTGCCATTGACCTGAACGGCTACGTGTTGCTGCACCCCAATCTCAAGCCCCAGACCACCA  
 30 ACTTCCGGGAGCCTGTGACTCTGGACTTCCTGGATGCGGAGCTAGAGGATGAGAACAAGGA  
 AGAGATCCGTGCGAGCATGATTGATGGCAACAAGGGCCACAAGCAGATCAGAACGTTGGTTC  
 AAGTCCCTGGATGAGAGGTACATAGATGAGGTGACACGGAACCTACACCTGGGTGCCTATAA  
 GGAGCACTAACTACAGCCTGGGGCTGGTGCTCCACCCCTACAGCACCTTCTACCTCCAAGC  
 CAATCTCAGTGACCAGATCCTGCAGGTCAAGTATTTTGAAGTTCTGCTCCCCAGCAGCTTT  
 35 GAGTCTGAAGGACACGTTTTTCATTGCTCCAGAGAGTACTGCAAGGACCTGAATGCCTCAG  
 ACAACAACACCGAGTTCTGAAAACTTTATTGAGCTCATGGAGAAAGTGACTCCAGACTC  
 CAAGCAGTGCAACAACCTTCTTGCACAACCTGATCTTGGACACGGGCATCACGCAGCAG  
 CTGGTAGAGCGTGTGTGGAGGGACCAGGATCTCAACACGTACAGCCTACTGGCCGTGTTTCG

665T60:0526260



CTGCCACAGACGGTGGCATCACCCGAGTCTTCCCCAACAGGCAGCTGAGGACTGGACAGA  
 GAACCCGTAGCCCTTCAATGCCAGCTTCTACCGCCGAGCCTGGATAAACCACGGTTATGTC  
 TTCAAGCCCCACACCAGGATGCCCTGTTAAGGCCGCTGGAGCTGGAGAATGACACTGTGG  
 GCATCCTCGTCAGCACAGCTGTGGAGCTCAGCCTAGGCAGGCGCACACTGAGGCCAGCAGT  
 5 GGTGGGCGTCAAGCTGGACCTAGAGGCTTGGGCTGAGAAGTTCAAGGTGCTAGCCAGCAAC  
 CGTACCCACCAAGACCAGCCTCAGAAGTGCGGCCCCAACAGCCACTGTGAGATGGACTGCG  
 AGGTTAACAATGAGGACTTACTCTGTGTCTCATTGATGATGGAGGATTCTTGGTGCTGTC  
 AAACCAGAACCATCAGTGGGACCAGGTGGGCAGGTTCTTCAGTGAGGTGGATGCCAACCTG  
 ATGCTGGCACTCTACAATAACTCCTTCTACACCCGCAAGGAGTCCTATGACTATCAGGCAG  
 10 CCTGTGCCCCCTCAGCCCCCTGGCAACCTGGGTGCTGCACCCCGGGGTGTCTTTGTGCCAC  
 CGTTGCAGATTTCTTAACCTGGCCTGGTGGACCTCTGCTGCCGCTGGTCCCTGTTCCAG  
 CAGCTTCTCTACGGCCTCATCTACCACAGCTGGTTCCAAGCAGACCCCGCGGAGGCCGAGG  
 GGAGCCCCGAGACGCGCGAGAGCAGCTGCGTCATGAAACAGACCCAGTACTACTTTCGGCTC  
 GGTAAACGCCTCCTACAACGCCATCATCGACTGCGGAACTGCTCCAGGCTGTTCCACGCG  
 15 CAGAGACTGACCAACACCAATCTTCTCTTTGTGGTGGCCGAGAAGCCGCTGTGCAGCCAGT  
 GCGAGGCTGGCCGGCTGCTGCAGAAGGAGACGCACTGCCAGCGGACGGCCCGGAGCAGTG  
 TGAGCTAGTGCAGAGACCGCGATACCGGAGAGGCCCGCACATCTGCTTCGACTACAACGCG  
 ACAGAAGATACCTCAGACTGTGGCCGCGGGGCC

#### 20 4 - human amino acid sequence

MAVPARTCGASRPGPARTARWPWPGCGPHPGPTRRPTSGPPRPLWLLLPLLPLLAAPGASA  
 YSFPQQHTMQHWARRLEQEVDGVMRIFGGVQQLREIYKDNRNLFVQENEPQKLVEKVAGD  
 IESLLDRKVQALKRLADAAENFQKAHRWQDNIKEEDIVYYDAKADAELDDPESEDVERGSK  
 ASTLRDLFIEDPNFKNKVNSYAAVQIPTDIYKGSTVILNELNWTEALENVFMENRRQDPT  
 25 LLWQVFGSATGVTRYYPATPWRAPKKIDLYDVRRRPWYIQGASSPKDMVIVDVSGSVSGL  
 TLKLMKTSVCEMLDTLSDDDYVNVASFNEKAQPVSCFTHLVQANVRNKKVFKEAVQGMVAK  
 GTTGKAGFEYAFDQLQNSNITRANCNMIMMFTDGGEDRVQDVFEKYNWPNRTVRVFTFS  
 VGQHNYDVTPLQWMACANKGYIFEIPSIGAIRINTQEYLDVLGRPMVLAGEAKVQWQTNV  
 YEDALGLGLVVTGTLPVFNLTQDGPGEKKNQLILGVMGIDVALNDIKRLTPNYTLGANGYV  
 30 FAIDLNGYVLLHPNLKPQTTNFREPVTLDFLDAELEDENKEEIRRSIDGNKGHKQIRTLV  
 KSLDERYIDEVTRNYTWVPIRSTNYSGLVLPYSTFYLQANLSDQILQVKYFEFLPSSF  
 ESEGHVFIAPREYCKDLNASDNNTFLKNFIELMEKVTSDSKQCNNFLLHNLILDGTITQQ  
 LVERVWRDQDLNTYSLAVFAATDGGITRVFPNKAEDWTENPEPFNASFYRRSLDNHGYV  
 FKPPHQDALLRPLELENDTVGILVSTAVELSLGRRTLRAVVGVKLDLEAWAEKFKVLASN  
 35 RTHQDQPKCGPNSHCCEMDCEVNNEDELLCVLIDDGGFLVLSNQNHWQDQVGRFFSEVDANL  
 MLALYNNSFYTRKESYDYQAACAPQPPGNLGAAPRGVFVPTVADFLNLAWWTSAAAWSLFQ  
 QLLYGLIYHSWFQADPAEAEGPSPETRESSCVMKQTQYYFGSVNASYNALIDCGNCSRLFHA  
 QRLTNTNLLFVVAEKPLCSQCEAGR

659760 0592650

## 5 - human amino acid sequence

MAVPARTCGASRPGPARTARWPWPGCGPHPGPGTRRPTSGPPRPLWLLLPLLLPLLAAPGASA  
 YSFPQQHTMQHWARRLEQEVDGVMRIFGGVQQLREIYKDNRNLFVQENEPQKLVEKVAGD  
 IESLLDRKVQALKRLADAAENFQKAHRWQDNIKEEDIVYYDAKADAELDDPESEDVERGSK  
 5 ASTLRDLDFIEDPNFKNVNYSYAAVQIPTDIYKGSTVILNELNWTEALENVFMENRRQDPT  
 LLWQVFGSATGVTRYYPATPWRAKKIDLYDVRRRPWYIQGASSPKDMV IIVDVSGSVSGL  
 TLKLMKTSVCEMLD TLSDDDYVNVASFNEKAQPVSCFTHLVQANVRNKKVFKEAVQGMVAK  
 GTTGYKAGFEYAFDQLQNSNITRANCNMIMMFTDGGEDRVQDVFEKYNWPNRTRVRVFTFS  
 VGQHNYDVTPLQWMACANKGYFFEIPSIGAIRINTQEYLDVLGRPMVLAGEAKQVQWTVN  
 10 YEDALGLGLVVTGTLPVFNLTQDGPGEKKNLILGVMGIDVALNDIKRLTPNYTLGANGYV  
 FAIDLNGYVLLHPNLKPQTTNFREPVTLDFLDAELEEDENKEEIRRSMIDGNKGHKQIRTLV  
 KSLDERYIDEVTRNYTWVPIRSTNYSGLVLPYSTFYQLQANLSDQILQVKYFEFLLPSSF  
 ESEGHVFIAPREYCKDLNASDNNTFLKNFIELMEKVTPDSKQCNNFLHNLILDTGITQQ  
 LVERVWRDQDLNTYSLLAVFAATDGGITRVFPNKAEDWTENPEPFNASFYRRSLDNHGYV  
 15 FKPPHQDALLRPLELENDTVGILVSTAVELSLGRRTLPAVVGVKLDLEAWAEKFKVLASN  
 RTHQDQPQKCGPNSHCEMDCEVNNEEDLLCVLIDDGGFLVLSNQNHQWDQVGRFFSEVDANL  
 MLALYNNSFYTRKESYDYQAACAPQPPGNLGAAPRGVFPVTVADFLNLAWWTSAAAWSLFQ  
 QLLYGLIYHSWFQADPAEAGSPETRESSCVMKQTQYYFGSVNASYNAIIDCGNCSRLFHA  
 QRLTNTNLLFVVAEKPLCSQCEAGRLLQKETHCPADGPEQCELVQ

20

## 6 - human amino acid sequence

MAVPARTCGASRPGPARTARWPWPGCGPHPGPGTRRPTSGPPRPLWLLLPLLLPLLAAPGASA  
 YSFPQQHTMQHWARRLEQEVDGVMRIFGGVQQLREIYKDNRNLFVQENEPQKLVEKVAGD  
 IESLLDRKVQALKRLADAAENFQKAHRWQDNIKEEDIVYYDAKADAELDDPESEDVERGSK  
 25 ASTLRDLDFIEDPNFKNVNYSYAAVQIPTDIYKGSTVILNELNWTEALENVFMENRRQDPT  
 LLWQVFGSATGVTRYYPATPWRAKKIDLYDVRRRPWYIQGASSPKDMV IIVDVSGSVSGL  
 TLKLMKTSVCEMLD TLSDDDYVNVASFNEKAQPVSCFTHLVQANVRNKKVFKEAVQGMVAK  
 GTTGYKAGFEYAFDQLQNSNITRANCNMIMMFTDGGEDRVQDVFEKYNWPNRTRVRVFTFS  
 VGQHNYDVTPLQWMACANKGYFFEIPSIGAIRINTQEYLDVLGRPMVLAGEAKQVQWTVN  
 30 YEDALGLGLVVTGTLPVFNLTQDGPGEKKNLILGVMGIDVALNDIKRLTPNYTLGANGYV  
 FAIDLNGYVLLHPNLKPQTTNFREPVTLDFLDAELEEDENKEEIRRSMIDGNKGHKQIRTLV  
 KSLDERYIDEVTRNYTWVPIRSTNYSGLVLPYSTFYQLQANLSDQILQVKYFEFLLPSSF  
 ESEGHVFIAPREYCKDLNASDNNTFLKNFIELMEKVTPDSKQCNNFLHNLILDTGITQQ  
 LVERVWRDQDLNTYSLLAVFAATDGGITRVFPNKAEDWTENPEPFNASFYRRSLDNHGYV  
 35 FKPPHQDALLRPLELENDTVGILVSTAVELSLGRRTLPAVVGVKLDLEAWAEKFKVLASN  
 RTHQDQPQKCGPNSHCEMDCEVNNEEDLLCVLIDDGGFLVLSNQNHQWDQVGRFFSEVDANL  
 MLALYNNSFYTRKESYDYQAACAPQPPGNLGAAPRGVFPVTVADFLNLAWWTSAAAWSLFQ  
 QLLYGLIYHSWFQADPAEAGSPETRESSCVMKQTQYYFGSVNASYNAIIDCGNCSRLFHA

667160"0552660

QRLTNTNLLFVVAEKPLCSQCEAGRLLQKETHCPADGPEQCELVQRPRYRRGPHICFDYNA  
TEDTSDCGRGA

**7 - human nucleotide sequence**

5 ATGGCCGGGCCGGGCTCGCCGCGCCGCGCTCCCGGGGGGCGCTCGGCGCTTCTCGCTGCCG  
CGCTTCTCTACGCCGCGCTGGGGGACGTGGTGCGCTCGGAGCAGCAGATACCGCTCTCCGT  
GGTGAAGCTCTGGGCCTCGGCTTTTGGTGGGGAGATAAAAATCCATTGCTGCTAAGTACTCC  
GGTTCACGCTTCTGCAAAAGAAATACAAAGAGTATGAGAAAGACGTTGCCATAGAAGAAA  
TTGATGGCCTCCAACCTGGTAAAGAAGCTGGCAAAAGAACATGGAAGAGATGTTTCACAAGAA  
10 GTCTGAGGCCGTCAGGCGTCTGGTGGAGGCTGCAGAAGAAGCACACCTGAAACATGAATTT  
GATGCAGACTTACAGTATGAATACTTCAATGCTGTGCTGATAAATGAAAGGGACAAAGACG  
GGAATTTTTTTGGAGCTGGGAAAGGAATTCATCTTAGCCCCAAATGACCATTTTAATAATTT  
GCCTGTGAACATCAGTCTAAGTGACGTCCAAGTACCAACGAACATGTACAACAAAGACCCCT  
GCAATTGTCAATGGGGTTTATTGGTCTGAATCTCTAAACAAAGTTTTTGTAGATAACTTTG  
15 ACCGTGACCCATCTCTCATATGGCAGTACTTTGGGAAGTGCAAAGGGCTTTTTTTAGGCAGTA  
TCCGGGGATTAAATGGGAACCAGATGAGAATGGAGTCATTGCCTTCGACTGCAGGAACCGA  
AAATGGTACATCCAGGCAGCAACTTCTCCGAAAAGACGTGGTCATTTTAGTTGACGTCAGTG  
GCAGCATGAAAGGACTCCGTCTGACTATCGCGAAGCAAACAGTCTCATCCATTTTGGATAC  
ACTTGGGGATGATGACTTCTTCAACATAATTGCTTATAATGAGGAGCTTCACTATGTGGAA  
20 CCTTGCCTGAATGGAACCTTTGGTGCAAGCCGACAGGACAAACAAAGAGCACTTCAGGGAGC  
ATCTGGACAAACTTTTTCGCCAAAGGAATTGGAATGTTGGATATAGCTCTGAATGAGGCCTT  
CAACATTCTGAGTGATTTCAACCACACGGGACAAGGAAGTATCTGCAGTCAGGCCATCATG  
CTCATAACTGATGGGGCGGTGGACACCTATGATACAATCTTTGCAAAAATACAATTGGCCAG  
ATCGAAAGGTTTCGCATCTTCACATACCTCATTTGGACGAGAGGCTGCGTTTGCAGACAATCT  
25 AAAGTGATGGCCTGTGCCAAACAAAGGATTTTTTACCCAGATCTCCACCTTGGCTGATGTG  
CAGGAGAATGTCATGGAATACCTTCACGTGCTTAGCCGGCCCCAAAGTCATCGACCAGGAGC  
ATGATGTGGTGTGGACCGAAGCTTACATTGACAGCACTCTGACTGATGATCAGGGCCCCGT  
CCTGATGACCACTGTAGCCATGCCTGTGTTTAGTAAGCAGAACGAAACCAGATCGAAGGGC  
ATTCTTCTGGGAGTGGTTGGCACAGATGTCCCAGTGAAAGAACTTCTGAAGACCATCCCCA  
30 AATACAAGTTAGGGATTACGGTTATGCCTTTGCAATCACAAATAATGGRTATATCCTGAC  
GCATCCGGAACCTCAGGCTGCTGTACGAAGAAGGAAAAAAGCGAAGGAAACCTAACTATAGT  
AGCGTTGACCTCTCTGAGGTGGAGTGGGAAGACCGAGATGACGTGTTGAGAAATGCTATGG  
TGAATCGAAAGACGGGGAAGTTTTCCATGGAGGTGAAGAAGACAGTGGACAAAGGGAAACG  
GGTTTTGGTGATGACAAATGACTACTATTATACAGACATCAAGGGTACTCCTTTTCAGTTTA  
35 GGTGTGGCGCTTTCCAGAGGTCATGGGAAATATTTCTTCCGAGGGAATGTAACCATCGAAG  
AAGGCCTGCATGACTTAGAACATCCCGATGTGTCTTGGCAGATGAATGGTCCTACTGCAA  
CACTGACCTACACCCTGAGCACCGCCATCTGTCTCAGTTAGAAGCGATTAAAGCTCTACCTA  
AAAGGCAAAGAACCTCTGCTCCAGTGTGATAAAGAATTGATCCAAGAAGTCCTTTTTTGACG

059150:05526260

CGGTGGTGAGTGCCCCATTGAAGCGTATTGGACCAGCCTGGCCCTCAACAAATCTGAAAA  
 TTCTGACAAGGGCGTGAGGTTGCCTTCCTCGGCACTCGCACGGGCCTCTCCAGAATCAAC  
 CTGTTTTGTCTGGGGCTGAGCAGCTCACCAATCAGGACTTCCTGAAAGCTGGCGACAAGGAGA  
 ACATTTTAAACGCAGACCATTTCCTCTCTGGTACCGAAGAGCCGCTGAGCAGATTCCAGG  
 5 GAGCTTCGTCTACTCGATCCCATTCAGCACTGGACCAGTCAATAAAAGCAATGTGGTGACA  
 GCAAGTACATCCATCCAGCTCCTGGATGAACGGAATCTCCTGTGGTGGCAGCTGTAGGCA  
 TTCAGATGAACTTGAATTTTCCAAAGGAAGTTCTGGACTGCCAGCAGACAGTGTGCTTC  
 CCTGGATGGCAAATGCTCCATCAGCTGTGATGATGAGACTGTGAATTGTTACCTCATAGAC  
 AATAATGGATTTATTTTGGTGTCTGAAGACTACACACAGACTGGAGACTTTTTTGGTGAGA  
 10 TCGAGGGAGCTGTGATGAACAAATTGCTAACAAATGGGCTCCTTTAAAGAATTACCCTTTA  
 TGACTIONACCAAGCCATGTGTAGAGCCAACAAGGAAAGCAGCGATGGCGCCCATGGCCTCCTG  
 GATCCTTATAATGCC'TTCCTCTCTGCAGTAAAATGGATCATGACAGAACTTGTCTTGTTC  
 TGGTGGAAATTTAACCTCTGCAGTTGGTGGCACTCCGATATGACAGCTAAAGCCCAGAAATT  
 GAAACAGACCC'TGGAGCCTTGTGATACTGAATATCCAGCATTCTGTCTCTGAGCGCACCATC  
 15 AAGGAGACTACAGGGAATAT'TGCTTGTGAAGACTGCTCCAAGTCTTTTGTCTATCCAGCAAA  
 TCCCAAGCAGCAACC'TGTTTCATGGTGGTGGTGGACAGCAGCTGCCTCTGTGAATCTGTGGC  
 CCCCATC

#### 8 - human nucleotide sequence

20 ATGGCCGGGCCGGGCTCGCCGCGCCGCGCGTCCCGGGGGGCTCGGCGCTTCTCGCTGCCG  
 CGCTTCTCTACGCCGCGCTGGGGGACGTGGTGGCTCGGAGCAGCAGATACCGCTCTCCGT  
 GGTGAAGCTCTGGGCCCTCGGCTTTTGGTGGGGAGATAAAATCCATTGCTGCTAAGTACTCC  
 GGT'TCCCAGCTTCTGCAAAAGAAATACAAAGAGTATGAGAAAGACGTTGCCATAGAAGAAA  
 TTGATGGCC'TCCAAC'TGGTAAAGAAGCTGGCAAAGAACATGGAAGAGATGTTTCAACAAGAA  
 25 GTCTGAGGCCGTGAGCGTCTGGTGGAGGCTGCAGAAGAAGCACACCTGAAACATGAATTT  
 GATGCAGACTTACAGTATGAATACTTCAATGCTGTGCTGATAAATGAAAGGGACAAAGACG  
 GGAATTTTTTGGAGCTGGGAAAGGAATTCATCTTAGCCCCAAATGACCATTTTAATAATTT  
 GCCTGTGAACATCAGTCTAAGTGACGTCCAAGTACCAACGAACATGTACAACAAAGACCCCT  
 GCAAT'TGTCAATGGGGTTTATTTGGTCTGAATCTCTAAACAAAGTTTTTGTAGATAACTTTG  
 30 ACCGTGACCCATCTCTCATATGGCAGTACTTTGGAAGTGCAAAGGGCTTTTTTAGGCAGTA  
 TCCGGGGATTAAATGGGAACCAGATGAGAATGGAGTCATTGCCTTCGACTGCAGGAACCGA  
 AAATGGTACATCCAGGCAGCAACTTCTCCGAAAGACGTGGTCAATTTTAGTTGACGTCAGTG  
 GCAGCATGAAAGGACTCCGTCTGACTATCGCGAAGCAAACAGTCTCATCCATTTTGGATAC  
 ACTTGGGGATGATGACTTCTTCAACATAATTGCTTATAATGAGGAGCTTCACTATGTGGAA  
 35 CCTTGCCTGAATGGAAC'TTGGTGAAGCCGACAGGACAAACAAAGAGCACTTCAGGGAGC  
 ATCTGGACAAACTTTTCGCCAAAGGAATTGGAATGTTGGATATAGCTCTGAATGAGGCCTT  
 CAACAT'TCTGAGTGATTTCAACCACACGGGACAAGGAAGTATCTGCAGTCAGGCCATCATG  
 CTCATAACTGATGGGGCGGTGGACACCTATGATACAATCTTTGCAAAATACAATTGGCCAG

05526200

ATCGAAAGGTTTCGCATCTTCACATACCTCATTGGACGAGAGGCTGCGTTTGAGACAATCT  
 AAAGTGGATGGCCTGTGCCAACAAAGGATTTTTTACCCAGATCTCCACCTTGGCTGATGTG  
 CAGGAGAATGTCATGGAATACCTTCACGTGCTTAGCCGGCCCAAAGTCATCGACCAGGAGC  
 ATGATGTGGTGTGGACCGAAGCTTACATTGACAGCACTCTGACTGATGATCAGGGCCCCGT  
 5 CCTGATGACCACTGTAGCCATGCCTGTGTTTAGTAAGCAGAACGAAACAGATCGAAGGGC  
 ATTCTTCTGGGAGTGGTTGGCACAGATGTCCCAGTGAAAGAACTTCTGAAGACCATCCCCA  
 AATACAAGTTAGGGATTACGGTTATGCCTTTGCAATCACAATAATGGRTATATCCTGAC  
 GCATCCGGAACCTCAGGCTGCTGTACGAAGAAGGAAAAAAGCGAAGGAAACCTAACTATAGT  
 AGCGTTGACCTCTCTGAGGTGGAGTGGGAAGACCGAGATGACGTGTTGAGAAATGCTATGG  
 10 TGAATCGAAAGACGGGGAAGTTTTCCATGGAGGTGAAGAAGACAGTGGACAAAGGGAAACG  
 GGTTTTGGTGATGACAAATGACTACTATTATACAGACATCAAGGGTACTCCTTTTCAGTTTA  
 GGTGTGGCGCTTTCCAGAGGTCATGGGAAATATTTCTTCCGAGGGAATGTAACCATCGAAG  
 AAGGCCCTGCATGACTTAGAACATCCCGATGTGTCCTTGGCAGATGAATGGTCCTACTGCAA  
 CACTGACCTACACCCTGAGCACCGCCATCTGTCTCAGTTAGAAGCGATTAAGCTCTACCTA  
 15 AAAGGCAAAGAACCTCTGCTCCAGTGTGATAAAGAATTGATCCAAGAAGTCCTTTTTGACG  
 CGGTGGTGAGTGGCCCCATTGAAGCGTATTGGACCAGCCTGGCCCTCAACAAATCTGAAAA  
 TTCTGACAAGGGCGTGGAGGTTGCCTTCTCGGCACTCGCACGGGCCTCTCCAGAATCAAC  
 CTGTTTGTGCGGGCTGAGCAGCTCACCAATCAGGACTTCTGAAAGCTGGCGACAAGGAGA  
 ACATTTTTTAACGCAGACCATTTCCCTCTCTGGTACCGAAGAGCCGCTGAGCAGATTCCAGG  
 20 GAGCTTCGTCTACTCGATCCCATTCAGCACTGGACCAGTCAATAAAAGCAATGTGGTGACA  
 GCAAGTACATCCATCCAGCTCCTGGATGAACGGAAATCTCCTGTGGTGGCAGCTGTAGGCA  
 TTCAGATGAAACTTGAATTTTTTCCAAAGGAAGTTCTGGACTGCCAGCAGACAGTGTGCTTC  
 CCTGGATGGCAAATGCTCCATCAGCTGTGATGATGAGACTGTGAATTGTTACCTCATAGAC  
 AATAATGGATTTATTTTGGTGTCTGAAGACTACACACAGACTGGAGACTTTTTTGGTGAGA  
 25 TCGAGGGAGCTGTGATGAACAAATTGCTAACAATGGGCTCCTTTAAAGAATTACCTTTTA  
 TGACTIONACCAAGCCATGTGTAGAGCCAACAAGGAAAGCAGCGATGGCGCCCATGGCCCTCCTG  
 GATCCTTATAATGCCTTCCTCTCTGCAGTAAAATGGATCATGACAGAACTTGTCTTGTTC  
 TGGTGGAAATTTAACCTCTGCAGTTGGTGGCACTCCGATATGACAGCTAAAGCCCAGAAATT  
 GAAACAGACCCTGGAGCCTTGTGATACTGAATATCCAGCATTGCTCTGAGCGCACCATC  
 30 AAGGAGACTACAGGGAATATTGCTTGTGAAGACTGCTCCAAGTCCTTTGTCATCCAGCAAA  
 TCCAAGCAGCAACCTGTTTCATGGTGGTGGTGGACAGCAGCTGCCTCTGTGAATCTGTGGC  
 CCCCATCACCATGGCACCCATTGAAATCAGGTATAATGAATCCCTTAAGTGTGAACGTCTA  
 AAG

35 9 - human nucleotide sequence

ATGGCCGGGCGGGCTCGCCGCGCCGCGCTCCCGGGGGGCTCGGCGCTTCTCGCTGCCG  
 CGCTTCTCTACGCCGCGCTGGGGGACGTGGTGGCTCGGAGCAGCAGATACCGCTCTCCGT  
 GGTGAAGCTCTGGGCCTCGGCTTTTGGTGGGAGATAAAATCCATTGCTGCTAAGTACTCC

00970:052220

GGTTCCAGCTTCTGCAAAAGAAATACAAAGAGTATGAGAAAGACGTTGCCATAGAAGAAA  
 TTGATGGCCTCCAACCTGGTAAAGAAGCTGGCAAAGAACATGGAAGAGATGTTTCACAAGAA  
 GTCTGAGGCCGTGAGCGTCTGGTGGAGGCTGCAGAAGAAGCACACCTGAAACATGAATTT  
 GATGCAGACTTACAGTATGAATACTTCAATGCTGTGCTGATAAATGAAAGGGACAAAGACG  
 5 GGAATTTTTTGGAGCTGGGAAAGGAATTCATCTTAGCCCCAAATGACCATTTTAATAATTT  
 GCCTGTGAACATCAGTCTAAGTGACGTCCAAGTACCAACGAACATGTACAACAAAGACCTT  
 GCAATTGTCAATGGGGTTTATTGGTCTGAATCTCTAAACAAAGTTTTTGTAGATAACTTTG  
 ACCGTGACCCATCTCTCATATGGCAGTACTTTGGAAGTGCAAAGGGCTTTTTTAGGCAGTA  
 TCCGGGGATTAAATGGGAACCAGATGAGAATGGAGTCATTGCCTTCGACTGCAGGAACCGA  
 10 AAATGGTACATCCAGGCAGCAACTTCTCCGAAAGACGTGGTCATTTTAGTTGACGTCAGTG  
 GCAGCATGAAAGGACTCCGTCTGACTATCGCGAAGCAAACAGTCTCATCCATTTTGATAC  
 ACTTGGGGATGATGACTTCTTCAACATAATTGCTTATAATGAGGAGCTTCACTATGTGGAA  
 CCTTGCCTGAATGGAACCTTTGGTGCAAGCCGACAGGACAAACAAAGAGCACTTCAGGGAGC  
 ATCTGGACAAACTTTTTGCCAAAGGAATTGGAATGTTGGATATAGCTCTGAATGAGGCCTT  
 15 CAACATTCTGAGTGATTTCAACCACACGGGACAAGGAAGTATCTGCAGTCAGGCCATCATG  
 CTCATAACTGATGGGGCGGTGGACACCTATGATACAATCTTTGCAAAATACAATTGGCCAG  
 ATCGAAAGGTTTCGCATCTTCACATACCTCATTGGACGAGAGGCTGCGTTTGCAGACAATCT  
 AAAGTGGATGGCCTGTGCCAACAAGGATTTTTTACCCAGATCTCCACCTTGGCTGATGTG  
 CAGGAGAATGTCATGGAATACCTTCACGTGCTTAGCCGGCCCCAAAGTCATCGACCAGGAGC  
 20 ATGATGTGGTGTGGACCGAAGCTTACATTGACAGCACTCTGACTGATGATCAGGGCCCCGT  
 CCTGATGACCACTGTAGCCATGCCTGTGTTTAGTAAGCAGAACGAAACCAGATCGAAGGGC  
 ATTCTTCTGGGAGTGGTTGGCACAGATGTCCCAGTGAAAGAACTTCTGAAGACCATCCCCA  
 AATACAAGTTAGGGATTACGGTTATGCCTTTGCAATCACAAATAATGGRTATATCCTGAC  
 GCATCCGGAACCTCAGGCTGCTGTACGAAGAAGGAAAAAAGCGAAGGAAACCTAACTATAGT  
 25 AGCGTTGACCTCTCTGAGGTGGAGTGGGAAGACCGAGATGACGTGTTGAGAAATGCTATGG  
 TGAATCGAAAGACGGGGAAGTTTTCCATGGAGGTGAAGAAGACAGTGGACAAAGGGAAACG  
 GGTTTTGGTGATGACAAATGACTACTATTATACAGACATCAAGGGTACTCCTTTTCAGTTTA  
 GGTGTGGCGCTTTCCAGAGGTGATGGGAAATATTTCTTCCGAGGGAATGTAACCATCGAAG  
 AAGGCCTGCATGACTTAGAACATCCCGATGTGTCCTTGGCAGATGAATGGTCCTACTGCAA  
 30 CACTGACCTACACCCTGAGCACCGCCATCTGTCTCAGTTAGAAGCGATTAAGCTCTACCTA  
 AAAGGCAAAGAACCTCTGCTCCAGTGTGATAAAGAATTGATCCAAGAAGTCTTTTTTGACG  
 CGGTGGTGAGTGCCCCATTGAAGCGTATTGGACCAGCCTGGCCCTCAACAAATCTGAAAA  
 TTCTGACAAGGGCGTGGAGGTTGCCTTCTCGGCACTCGCACGGGCCTCTCCAGAATCAAC  
 CTGTTTGTGCGGGCTGAGCAGCTCACCAATCAGGACTTCTTGAAAGCTGGCGACAAGGAGA  
 35 ACATTTTTTAACGCAGACCATTTCCCTCTCTGGTACCGAAGAGCCGCTGAGCAGATTCCAGG  
 GAGCTTCGTCTACTCGATCCCATTCAGCACTGGACCAGTCAATAAAAGCAATGTGGTGACA  
 GCAAGTACATCCATCCAGCTCCTGGATGAACGGAATCTCCTGTGGTGGCAGCTGTAGGCA  
 TTCAGATGAACTTGAATTTTTTCAAAGGAAGTTCTGGACTGCCAGCAGACAGTGTGCTTC

5

## 15

20

## 35

MAGPGSPRRASRGASALLAAALLYAALGDVVRSEQQIPLSVVKLWASAFGGEIKSIAAKYS  
GSQLLQKKYKEYEKDVAIEEIDGLQLVKKLAKNMEEMFHKKSEAVRRLVEAAEEAHLKHEF  
DADLQYEFNAVLINERDKDGNFLELGKEFILAPNDHFNNLPVNISLSDVQVPTNMYNKDP  
AIVNGVYWSESLNKVFVDNFDRDPSLIWQYFGSAKGFFRQYPGIKWEPPDENGVIADFCDNR  
KWYIQAATS PKDQVILVDVSGSMKGLRLTLIAKQTVSSILDTLGDDDDFNIIAYNEELHYVE

PCLNGTLVQADRTNKEHFREHLDKLFAKGIGMLDIALNEAFNILSDFNHTGQGSICSQAIM  
 LITDGAVDYDTIFAKYNWPDRKVRIPTYLIGREAAAFADNLKWMACANKGFFTQISTLADV  
 QENVMEYLHVLSRPKVIDQEHDVVWTEAYIDSTLTDDQGPVLMTTVAMPVFSKQNETRSKG  
 ILLGVVGTDVPVKELLKTIPKYKLGIGHYAFAITNNGYILTHPELRLLYEEGKKRRKPNYS  
 5 SVDLSEVEWEDRDDVLRNAMVNRKTGKFSMEVKKTVDKGKRVLMVTNDYYYTDIKGTPFSL  
 GVALSRGHGKYFFRGNVTIEEGLHDLEHPDVSLADEWSYCNTDLHPEHRHLSQLEAIKLYL  
 KGKEPLLQCDKELIQEVLFDVVSAPIEAYWTSALNKSSENSDKGVEVAFLGTRTGLSRIN  
 LFVGAEQLTNQDFLKAGDKENIFNADHFLWYRRAAEQIPGSFVYSIPFSTGPNKSNVVT  
 ASTSIQLLDERKSPVVAAVGIQMKLEFFQRFWTASRQCASLDGKCSISCDDETVNCYLID  
 10 NNGFILVSEDTYTQTDFFGEIEGAVMNKLLTMGSFKRITLYDYQAMCRANKESSDGAHGLL  
 DPYNAFLSAVKWIMTELVLFLVEFNLCSSWWHSDMTAKAQKLKQTLPCDTEYPAFVSERTI  
 KETTGNIACEDCSKSFVIQQIPSSNLFMVVDSSCLCESVAPITMAPIEIRYNESLK CERL  
 K

15 **12 - human amino acid sequence**

MAGPGSPRRASRGASALLAAALLYAALGDVVRSEQQIPLSVVKLWASAFGGEIKSIAAKYS  
 GSQLLQKKYKEYEKDVAIEEIDGLQLVKKLAKNMEEMFHKKSEAVRRLVEAAEEAHLKHEF  
 DADLQYEFNAVLINERDKDGNFLELGKEFILAPNDHFNNLPVNISLSDVQVPTNMYNKDP  
 AIVNGVYWSES LNKFVDNFDRDPSLIWQYFGSAKGFFRQYPGIKWEPDENGVI AFDCRNR  
 20 KWIYAATSPKDVVILVDVSGSMKGLRLTIKQTVSSILDTLGDDDFNIIAYNEELHYVE  
 PCLNGTLVQADRTNKEHFREHLDKLFAKGIGMLDIALNEAFNILSDFNHTGQGSICSQAIM  
 LITDGAVDYDTIFAKYNWPDRKVRIPTYLIGREAAAFADNLKWMACANKGFFTQISTLADV  
 QENVMEYLHVLSRPKVIDQEHDVVWTEAYIDSTLTDDQGPVLMTTVAMPVFSKQNETRSKG  
 ILLGVVGTDVPVKELLKTIPKYKLGIGHYAFAITNNGYILTHPELRLLYEEGKKRRKPNYS  
 25 SVDLSEVEWEDRDDVLRNAMVNRKTGKFSMEVKKTVDKGKRVLMVTNDYYYTDIKGTPFSL  
 GVALSRGHGKYFFRGNVTIEEGLHDLEHPDVSLADEWSYCNTDLHPEHRHLSQLEAIKLYL  
 KGKEPLLQCDKELIQEVLFDVVSAPIEAYWTSALNKSSENSDKGVEVAFLGTRTGLSRIN  
 LFVGAEQLTNQDFLKAGDKENIFNADHFLWYRRAAEQIPGSFVYSIPFSTGPNKSNVVT  
 ASTSIQLLDERKSPVVAAVGIQMKLEFFQRFWTASRQCASLDGKCSISCDDETVNCYLID  
 30 NNGFILVSEDTYTQTDFFGEIEGAVMNKLLTMGSFKRITLYDYQAMCRANKESSDGAHGLL  
 DPYNAFLSAVKWIMTELVLFLVEFNLCSSWWHSDMTAKAQKLKQTLPCDTEYPAFVSERTI  
 KETTGNIACEDCSKSFVIQQIPSSNLFMVVDSSCLCESVAPITMAPIEIRYNESLK CERL  
 KAKKIRRRPESCHGFHPEENARECGGAP

35 **13 - human nucleotide sequence**

AGTGGCCTCCTGAGAAGCAGCTTGTTTCGTGGGCTCCGAGAAGGTCTCCGACAGGAAGTTCC  
 TGACACCTGAGGACGAGGCCAGCGTGTTACCCCTGGACCGCTTCCCCTGTGGTACCGCCA  
 GGCCTCAGAGCATCCTGCTGGCAGCTTCGTCTTCAACCTCCGCTGGGCAGAAGGACCAGAA



AGTGC GGGTGAACCCATGGTGGTGACGGCAAGCACAGCTGTGGCGGTGACCGTGGACAAGA  
 GGACAGCCATTGCTGCAGCCGCGGGCGTCCAAATGAAGCTGGAATTCCTCCAGCGCAAATT  
 CTGGGCGGCAACGCGGCAGTGCAGCACTGTGGATGGGCCGTGCACACAGAGCTGCGAGGAC  
 AGTGATCTGGACTGCTTCGTCATCGACAACAACGGGTTCAATTCTGATCTCCAAGAGGTCCC  
 5 GAGAGACGGGAAGATTTCTGGGGGAGGTGGATGGTGCTGTCCTGACCCAGCTGCTCAGCAT  
 GGGGGTGTTCAGCCAAGTGACTATGTATGACTATCAGGCCATGTGCAAACCTCGAGTCAC  
 CACCACAGTGCAGCCCAGCCCCTGGTCAGCCCAATTTCTGCCTTCTTGACGGCGACCAGGT  
 GGCTGCTGCAGGAGCTGGTGCTGTTCTGCTGGAGTGGAGTGTCTGGGGCTCCTGGTACGA  
 CAGAGGGGCCGAGGCCAAAAGTGTCTTCCATCACTCCCACAAACACAAGAAGCAGGACCCG  
 10 CTGCAGCCCTGCGACACGGAGTACCCCGTGTTCGTGTACCAGCCGGCCATCCGGGAGGCCA  
 ACGGGATCGTGGAGTGCAGGGCCCTGCCAGAAGGTATTTGTGGTGCAGCAGATTCCCAACAG  
 TAACCTCCTCCTCCTGGTGACAGACCCACCTGTGACTGCAGCATCTTCCCACCACTG

#### 14 - human nucleotide sequence

15 AGTGGCCTCCTGAGAAGCAGCTTGTTTCGTGGGCTCCGAGAAGGTCTCCGACAGGAAGTTCC  
 TGACACCTGAGGACGAGGCCAGCGTGTTACCCCTGGACCGCTTCCCGCTGTGGTACCGCCA  
 GGCCTCAGAGCATCCTGCTGGCAGCTTCGTCTTCAACCTCCGCTGGGCAGAAGGACCAGAA  
 AGTGC GGGTGAACCCATGGTGGTGACGGCAAGCACAGCTGTGGCGGTGACCGTGGACAAGA  
 GGACAGCCATTGCTGCAGCCGCGGGCGTCCAAATGAAGCTGGAATTCCTCCAGCGCAAATT  
 20 CTGGGCGGCAACGCGGCAGTGCAGCACTGTGGATGGGCCGTGCACACAGAGCTGCGAGGAC  
 AGTGATCTGGACTGCTTCGTCATCGACAACAACGGGTTCAATTCTGATCTCCAAGAGGTCCC  
 GAGAGACGGGAAGATTTCTGGGGGAGGTGGATGGTGCTGTCCTGACCCAGCTGCTCAGCAT  
 GGGGGTGTTCAGCCAAGTGACTATGTATGACTATCAGGCCATGTGCAAACCTCGAGTCAC  
 CACCACAGTGCAGCCCAGCCCCTGGTCAGCCCAATTTCTGCCTTCTTGACGGCGACCAGGT  
 25 GGCTGCTGCAGGAGCTGGTGCTGTTCTGCTGGAGTGGAGTGTCTGGGGCTCCTGGTACGA  
 CAGAGGGGCCGAGGCCAAAAGTGTCTTCCATCACTCCCACAAACACAAGAAGCAGGACCCG  
 CTGCAGCCCTGCGACACGGAGTACCCCGTGTTCGTGTACCAGCCGGCCATCCGGGAGGCCA  
 ACGGGATCGTGGAGTGCAGGGCCCTGCCAGAAGGTATTTGTGGTGCAGCAGATTCCCAACAG  
 TAACCTCCTCCTCCTGGTGACAGACCCACCTGTGACTGCAGCATCTTCCCACCACTGCTG  
 30 CAGGAGGCGACAGAAGTCAAATATAATGCCTCTGTCAAATGTGACCGGATGCGC

#### 15 - human nucleotide sequence

AGTGGCCTCCTGAGAAGCAGCTTGTTTCGTGGGCTCCGAGAAGGTCTCCGACAGGAAGTTCC  
 TGACACCTGAGGACGAGGCCAGCGTGTTACCCCTGGACCGCTTCCCGCTGTGGTACCGCCA  
 35 GGCCTCAGAGCATCCTGCTGGCAGCTTCGTCTTCAACCTCCGCTGGGCAGAAGGACCAGAA  
 AGTGC GGGTGAACCCATGGTGGTGACGGCAAGCACAGCTGTGGCGGTGACCGTGGACAAGA  
 GGACAGCCATTGCTGCAGCCGCGGGCGTCCAAATGAAGCTGGAATTCCTCCAGCGCAAATT  
 CTGGGCGGCAACGCGGCAGTGCAGCACTGTGGATGGGCCGTGCACACAGAGCTGCGAGGAC

05526260

AGTGATCTGGACTGCTTCGTCATCGACAACAACGGGTTTCATTCTGATCTCCAAGAGGTCCC  
 GAGAGACGGGAAGATTTCTGGGGGAGGTGGATGGTGCTGTCTTGACCCAGCTGCTCAGCAT  
 GGGGGTGTTCAGCCAAGTGACTATGTATGACTATCAGGCCATGTGCAAACCTCGAGTCAC  
 CACCACAGTGCAGCCCAGCCCCTGGTCAGCCCAATTTCTGCCTTCTTGACGGCGACCAGGT  
 5 GGCTGCTGCAGGAGCTGGTGCTGTTCTCTGCTGGAGTGGAGTGTCTGGGGCTCCTGGTACGA  
 CAGAGGGGGCCGAGGCCAAAAGTGTCTTCCATCACTCCCACAAACACAAGAAGCAGGACCCG  
 CTGCAGCCCTGCGACACGGAGTACCCCGTGTTCGTGTACCAGCCGGCCATCCGGGAGGCCA  
 ACGGGATCGTGGAGTGCGGGGCCCTGCCAGAAGGTATTTGTGGTGCAGCAGATTCCCAACAG  
 TAACCTCCTCCTCCTGGTGACAGACCCACCTGTGACTGCAGCATCTTCCCACCAGTGCTG  
 10 CAGGAGGCGACAGAAGTCAAATATAATGCCTCTGTCAAATGTGACCGGATGCGCTCCCAGA  
 AGCTCCGCCGGCGACCAGACTCCTGCCACGCCTTCCATCCAGAGGAGAATGCCCAGGACTG  
 CGGCGGCGCCTCG

#### 16 - human amino acid sequence

15 SGLLRSSLFVGSEKVS DRKFLTPED EASVFTLDRFPLWYRQASEHPAGSFVFNLRWAEGPE  
 SAGEPMVVTASTAVAVTVDKRTAIAAAAGVQMKLEFLQRKFWAATRQCSTVDGPCTQSCED  
 SDLDCFVIDNNGFILISKRSRETGRFLGEVDGAVLTQLLSMGVFSQVTMYDYQAMCKPSSH  
 HHSAAQPLVSPISAFLTATRWLLQELVLFLEWSVWGSWYDRGAEAKSVFHSHKHKKQDP  
 LQPCDTEYPVFVYQPAIREANGIVECGPCQKV FVVQQIPNSNLLLLVTDPTCDCSIFPPV

#### 17 - human amino acid sequence

20 SGLLRSSLFVGSEKVS DRKFLTPED EASVFTLDRFPLWYRQASEHPAGSFVFNLRWAEGPE  
 SAGEPMVVTASTAVAVTVDKRTAIAAAAGVQMKLEFLQRKFWAATRQCSTVDGPCTQSCED  
 SDLDCFVIDNNGFILISKRSRETGRFLGEVDGAVLTQLLSMGVFSQVTMYDYQAMCKPSSH  
 25 HHSAAQPLVSPISAFLTATRWLLQELVLFLEWSVWGSWYDRGAEAKSVFHSHKHKKQDP  
 LQPCDTEYPVFVYQPAIREANGIVECGPCQKV FVVQQIPNSNLLLLVTDPTCDCSIFPPVL  
 QEATEVKYNASVKCDMR

#### 18 - human amino acid sequence

30 SGLLRSSLFVGSEKVS DRKFLTPED EASVFTLDRFPLWYRQASEHPAGSFVFNLRWAEGPE  
 SAGEPMVVTASTAVAVTVDKRTAIAAAAGVQMKLEFLQRKFWAATRQCSTVDGPCTQSCED  
 SDLDCFVIDNNGFILISKRSRETGRFLGEVDGAVLTQLLSMGVFSQVTMYDYQAMCKPSSH  
 HHSAAQPLVSPISAFLTATRWLLQELVLFLEWSVWGSWYDRGAEAKSVFHSHKHKKQDP  
 LQPCDTEYPVFVYQPAIREANGIVECGPCQKV FVVQQIPNSNLLLLVTDPTCDCSIFPPVL  
 35 QEATEVKYNASVKCDMRMSQKLRRRPDSCHAFHPEENAQDCGAS

039750:052620

## 19 - human alpha2 delta-2 nucleotide sequence

CGGGCAGCGCAGCCCGCAGAGGCGCTGCGGCCCGTGACGCCCCGGAGGCCCTCGCGGAGA  
 AGGCGGCGGCGGAGGAGAGGCCGAGTTACCGCCCCCGCCCCGCGCCCCCAACCCCGCCG  
 CCGCCGCGCGCCGCCACTGCCCCCCTCCCCGCGGCGCCGCATCTTGAATGGAAACATG  
 5 GCGGTGCCGGCTCGGACCTGCGGCGCCTCTCGGCCCGGCCAGCGCGGACTGCGCGCCCT  
 GGCCCGGTGCGGCCCCCACCCTGGCCCCGGCACCCGGCGCCGACGTCCGGGCCCCCGCG  
 CCCGCTGTGGCTGCTGCTGCCGCTTCTACCGCTGCTCGCCGCCCGCGCCTCTGCCTAC  
 AGCTTCCCCCAGCAGCACACGATGCAGCACTGGGCCCGCGTCTGGAGCAGGAGGTGACG  
 GCGTGATGCGGATTTTTGGAGGCGTCCAGCAGCTCCGTGAGATTTACAAGGACAACCGGAA  
 10 CCTGTTGAGGTACAGGAGAATGAGCCTCAGAAGTTGGTGGAGAAGGTGGCAGGGGACATT  
 GAGAGCCTTCTGGACAGGAAGGTGCAGGCCCTGAAGAGACTGGCTGATGCTGCAGAGAACT  
 TCCAGAAAGCACACCGCTGGCAGGACAACATCAAGGAGGAAGACATCGTGTACTATGACGC  
 CAAGGCTGACGCTGAGCTGGACGACCCTGAGAGTGAGGATGTGGAAAGGGGTCTAAGGCC  
 AGCACCCCTAAGGCTGGACTTCATCGAGGACCCAACTTCAAGAAACAAGGTCAACTATTTCAT  
 15 ACGCGGCTGTACAGATCCCTACGGACATCTACAAAGGCTCCACTGTCATCCTCAATGAGCT  
 CAACTGGACAGAGGCCCTGGAGAATGTGTTTCATGGAAAACCGCAGACAAGACCCCACTG  
 CTGTGGCAGGTCTTCGGCAGCGCCACAGGAGTCACTCGCTACTACCCGGCCACCCCGTGGC  
 GAGCCCCCAAGAAGATCGACCTGTACGATGTCCGAAGGAGACCCTGGTATATCCAGGGGGC  
 CTCGTACCCCAAAGACATGGTCATCATCGTGGATGTGAGTGGCAGTGTGAGCGGCCTGACC  
 20 CTGAAGCTGATGAAGACATCTGTCTGCGAGATGCTGGACACGCTGTCTGATGATGACTATG  
 TGAATGTGGCCTCGTTCAACGAGAAGGCACAGCCTGTGTGTCATGCTTCACACACCTGGTGCA  
 GGCCAATGTGCGCAACAAGAAGGTGTTCAAGGAAGCTGTGCAGGGCATGGTGGCCAAGGGC  
 ACCACAGGCTACAAGGCCGGCTTTGAGTATGCCTTTGACCAGCTGCAGAACTCCAACATCA  
 CTCGGGCCAACTGCAACAAGATGATCATGATGTTACGGATGGTGGTGAGGACCGCGTGCA  
 25 GGACGTCTTTGAGAAGTACAATTGGCCAAACCGGACGGTGCGCGTGTTTACTTTCTCCGTG  
 GGGCAGCATAACTATGACGTCACACCGCTGCAGTGGATGGCCTGTGCCAACAAAGGCTACT  
 ATTTTGAGATCCCTTCCATCGGAGCCATCCGCATCAACACACAGGAATATCTAGATGTGTT  
 GGGCAGGCCCATGGTGCTGGCAGGCAAGGAGGCCAAGCAGGTTTCAGTGGACCAACGTGTAT  
 GAGGATGCACTGGGACTGGGGTTGGTGGTAACAGGGACCCTCCCTGTTTTCAACCTGACAC  
 30 AGGATGGCCCTGGGGAAAAGAAGAACAGCTGATCCTGGGCGTGATGGGCATTGACGTGGC  
 TCTGAATGACATCAAGAGGCTGACCCCAACTACACGCTTGGAGCCAACGGCTATGTGTTT  
 GCCATTGACCTGAACGGCTACGTGTTGCTGCACCCCAATCTCAAGCCCCAGACCACCAACT  
 TCCGGGAGCCTGTGACTCTGGACTTCTGGATGCGGAGCTAGAGGATGAGAACAAGGAAGA  
 GATCCGTGCGGAGCATGATTGATGGCAACAAGGGCCACAAGCAGATCAGAACGTTGGTCAAG  
 35 TCCCTGGATGAGAGGTACATAGATGAGGTGACACGGAATAACCTGGGTGCCTATAAGGA  
 GCACTAACTACAGCCTGGGGCTGGTGCTCCACCCCTACAGCACCTTCTACCTCCAAGCCAA  
 TCTCAGTGACCAGATCCTGCAGGTCAAGTATTTTGAAGTTCTGCTCCCCAGCAGCTTTGAG  
 TCTGAAGGACACGTTTTTCATTGCTCCAGAGAGTACTGCAAGGACCTGAATGCCTCAGACA

[illegible]

TGGGACCACATGCCACTGCCTGCACCTTTTCGGCAGAGGAACCCCCACCAGACATCACCCCTT  
 TGCCTTAGCAGGGGTGACTTTGTCTCTCCTGGCTGGGCCATCCTTCCGCCAATCTGGCCCT  
 TACACACTCAGGCCTGTGCCCCACTCCCTATCTCCTTCCCACCCCTACACACACACTCCCTG  
 CTTGCAGGAGGCCAAACTGTCCCTCCCTTGCTGAACACACACACACACACACACACAGG  
 5 TGGGGACTGGGCACAGCTCTTCACACCATTTCATTCTGGTCATTTCCCCCAAAGGCATCCCA  
 GCCTGGGGGCCAGTGGGGAACTGAGGGCAAGGGGATATAGTGATGGGGCTCAGATGGACTG  
 GGAGGAGGGGGAGGGTGATGCATTAATTAATGGCTTCGTTAATTAATGTCATGTTGCTTGT  
 CGCTTTCTCAGTGTGTGTGTGTGGTCCATGCCCACTGCTGGTGCCAGGGTGGGTGTCCATG  
 TGCACCCGGCCTGGATGCCAGCTGTGTCTTCGGGGGCGTGCCTGTAAGTGTAGTGTAGTC  
 10 AGGTGCTCAATGGAGAATATAAACATATACAGAAAAATATATATTTTAAAGTTTAAAAACA  
 GAAAAACAGACAAAAACAATCCCCATCAGGTAGCTGTCTAACCCCCAGCTGGGTCTAATCCT  
 TCTCATTACCCACCCGACCTGGCTGCCCTCACCTTGGGCTGGGGGACTGGGGGGCCATTT  
 CCTTTTCTCTGCCCTTTTTTTGTGTCTTCTATTTTGTACAGACAAGTTGGAAAAACAACAGC  
 GACAAAAAGTCAAGAACTTTGTAAAATATCGTGTGTGTGATTCTTGTAATAATATTTTC  
 15 AAATGGTTTATTACAGAAGATCAGTTATTAAATAATGTTTCATATTTTCACTTC

#### 20- human alpha2 delta-2 amino acid sequence

MAVPARTCGASRPGPARTARPWPGCGPHGPGTRRPTSGPPRPLWLLLPLLLPLLAAPGASA  
 YSFPQQHTMQHWARRLEQEVDGVMRIFGGVQQLREIYKDNRLFEVQENEPQKLVEKVAGD  
 20 IESLLDRKVQALKRLADAAENFQKAHRWQDNIKEEDIVYYDAKADAELDDPESEDVERGSK  
 ASTLRLDFIEDPNFKNKVNYSYAAVQIPTDIYKGSTVILNELNWTEALENVFMENRRQDPT  
 LLWQVFGSATGVTRYYPATPWRAPKKIDLYDVRPPWYIQGASSPKDMVIIIDVSGSVSGL  
 TLKLMKTSVCEMLDTLSDDDYVNVASFNEKAQPVSCFTHLVQANVRNKKVFKEAVQGMVAK  
 GTTGKAGFEYAFDQLQNSNITRANCNKMMIMFTDGGEDRVQDVFEKYNWPNRTRVRVFTFS  
 25 VGQHNYDVTPLQWMACANKGYIFEI PSIGAIRINTQEYLDVLGRPMVLAGEAKQVQWNTNV  
 YEDALGLGLVVTGTLPVFNLTQDGPGEKKNLILGVMGIDVALNDIKRLTPNYTLGANGYV  
 FAIDLNGYVLLHPNLKPQTTFNREPVTLDFLDAELEDENKEEIRSRMIDGNKGHKQIRTLV  
 KSLDERYIDEVTRNYTWVPIRSTNYSGLVLPYSTFYLQANLSDQILQVKYFEFLLPSSF  
 ESEGHVFIAPREYCKDLNASDNNTFLKNFIELMEKVTPDSKQCNNFLLHNLILDTGITQQ  
 30 LVERVWRDQDLNTYSLLAVFAATDGGITRVFPNKAEDWTENPEPFNASFYRRSLDNHGYV  
 FKPPHQDALLRPLELENDTVGILVSTAVELSLGRRTLPAVVGKLDLEAWAEKFKVLASN  
 RTHQDQPKCGPNSHCEMDCEVNNEDELLCVLIDDGGFLVLSNQNHWQDQVGRFFSEVDANL  
 MLALYNNSFYTRKESYDYQAACAPQPPGNLGAAPRGVFVPTVADFLNLAWWTSAAAWSLFQ  
 QLLYGLIYHSWFQADPAEAEPSPETRESSVMKQTQYYFGSVNASYNAIIDCGNCSRLFHA  
 35 QRLTNTNLLFVVAEKPLCSQCEAGRLQKETHCPADGPEQCELVQRPRYRRGPHICFDYNA  
 TEDTSDCGRGASFPPSLGVLVSLQLLLLLLGLPPRPQPQVLVHASRRL

659T60"05526260

## 21 - human alpha2 delta-3 nucleotide sequence

TACTATAGGGCGGCCGGAATTCGGCACGAGGCGGCGGAGCGGAGCAGGCAGCCCCGCG  
 CGCTCGCCACCGCCCGCTCCGCGCAGCTCCCCGCGGCCGCTCTCGTCGCCGCCGAGCGG  
 GCGCGTCGGAGGGAGCCCAGCATGGCCGGGCGGGCTCGCCGCGCCGCGCTCCCGGGGGG  
 5 CCTCGGCGCTTCTCGCTGCCGCGCTTCTCTACGCCGCGCTGGGGGACGTGGTGCCTCGGA  
 GCAGCAGATACCGCTCTCCGTGGTGAAGCTCTGGGCCTCGGCTTTTGGTGGGGAGATAAAA  
 TCCATTGCTGCTAAGTACTCCGGTTCCCAGCTTCTGCAAAAGAAATACAAAGAGTATGAGA  
 AAGACGTTGCCATAGAAGAAATTGATGGCCTCCAAGTAAAGAAGCTGGCAAAGAACAT  
 GGAAGAGATGTTTCAACAAGAAGTCTGAGGCCGTGAGGCGTCTGGTGGAGGCTGCAGAAGAA  
 10 GCACACCTGAAACATGAATTTGATGCAGACTTACAGTATGAATACTTCAATGCTGTGCTGA  
 TAAATGAAAGGGACAAAGACGGGAATTTTTTGGAGCTGGGAAAGGAATTCATCTTAGCCCC  
 AAATGACCATTTTAATAATTTGCCTGTGAACATCAGTCTAAGTGACGTCCAAGTACCAACG  
 AACATGTACAACAAAGACCCTGCAATTGTCAATGGGGTTTATTGGTCTGAATCTCTAAACA  
 AAGTTTTTGTAGATAACTTTGACCGTGACCCATCTCTCATATGGCAGTACTTTGGAAGTGC  
 15 AAAGGGCTTTTTTAGGCAGTATCCGGGGATTAAATGGGAACCAGATGAGAATGGAGTCATT  
 GCCTTCGACTGCAGGAACCGAAAATGGTACATCCAGGCAGCAACTTCTCCGAAAGACGTGG  
 TCATTTTAGTTGACGTGAGTGGCAGCATGAAAGGACTCCGTCTGACTATCGCGAAGCAAAC  
 AGTCTCATCCATTTTGGATACACTTGGGGATGATGACTTCTTCAACATAATTGCTTATAAT  
 GAGGAGCTTCACTATGTGGAACCTTGCCGAATGGAACCTTTGGTGAAGCCGACAGGACAA  
 20 ACAAAGAGCACTTCAGGGAGCATCTGGACAAACTTTTCGCCAAAGGAATTGGAATGTTGGA  
 TATAGCTCTGAATGAGGCCCTTCAACATTCTGAGTGATTTCAACCACACGGGACAAGGAAGT  
 ATCTGCAGTCAGGCCATCATGCTCATAACTGATGGGGCGGTGGACACCTATGATACAATCT  
 TTGCAAAATACAATTGGCCAGATCGAAAGGTTTCGCATCTTACATACCTCATTGGACGAGA  
 GGCTGCGTTTGCAGACAATCTAAAGTGGATGGCCTGTGCCAACAAAGGATTTTTTACCCAG  
 25 ATCTCCACCTTGGCTGATGTGCAGGAGAATGTGATGGAATACCTTCACGTGCTTAGCCGGC  
 CCAAAGTCATCGACCAGGAGCATGATGTGGTGTGGACCGAAGCTTACATTGACAGCACTCT  
 GACTGATGATCAGGGCCCCGTCCTGATGACCACTGTAGCCATGCCTGTGTTTTAGTAAGCAG  
 AACGAAACCAGATCGAAGGGCATTCTTCTGGGAGTGGTTGGCACAGATGTCCAGTGAAAG  
 AACTTCTGAAGACCATCCCCAAATACAAGTTAGGGATTACAGGTTATGCCTTTGCAATCAC  
 30 AAATAATGGRTATATCCTGACGCATCCGAACTCAGGCTGCTGTACGAAGAAGGAAAAAAG  
 CGAAGGAAACCTAATATAGTAGCGTTGACCTCTCTGAGGTGGAGTGGGAAGACCGAGATG  
 ACGTGTGAGAAATGCTATGGTGAATCGAAAGACGGGGAAGTTTTCCATGGAGGTGAAGAA  
 GACAGTGGACAAAGGGAACGGGTTTTTGGTGTATGACAAATGACTACTATTATACAGACATC  
 AAGGGTACTCCTTTTCACTTTAGGTGTGGCGCTTTCCAGAGGTGATGGGAAATATTTCTTCC  
 35 GAGGGAATGTAACCATCGAAGAAGGCCTGCATGACTTAGAACATCCCGATGTGTCTTGGC  
 AGATGAATGGTCCCTACTGCAACACTGACCTACACCCTGAGCACCGCCATCTGTCTCAGTTA  
 GAAGCGATTAAGCTCTACCTAAAAGGCAAGAACCTCTGCTCCAGTGTGATAAAGAATTGA  
 TCCAAGAAGTCCTTTTTGACGCGGTGGTGAAGTGGCCCCATTGAAGCGTATTGGACCAGCCT

009750 052620  
 009750 052620

GGCCCTCAACAAATCTGAAAATTCTGACAAGGGCGTGGAGGTTGCCTTCTCGGCACTCGC  
 ACGGGCCTCTCCAGAATCAACCTGTTTGTGCGGGGCTGAGCAGCTCACCAATCAGGACTTCC  
 TGAAAGCTGGCGACAAGGAGAACATTTTAAACGCAGACCATTTCCCTCTCTGGTACCGAAG  
 AGCCGCTGAGCAGATTCCAGGGAGCTTCGTCTACTCGATCCCATTACAGCACTGGACCAGTC  
 5 AATAAAAGCAATGTGGTGACAGCAAGTACATCCATCCAGCTCCTGGATGAACGGAAATCTC  
 CTGTGGTGGCAGCTGTAGGCATTAGATGAACTTGAATTTTTCCAAAGGAAGTTCTGGAC  
 TGCCAGCAGACAGTGTGCTTCCCTGGATGGCAAATGCTCCATCAGCTGTGATGATGAGACT  
 GTGAATTGTTACCTCATAGACAATAATGGATTTATTTTGGTGTCTGAAGACTACACACAGA  
 CTGGAGACTTTTTTGGTGAGATCGAGGGAGCTGTGATGAACAAATTGCTAACAATGGGCTC  
 10 CTTTAAAAGAATTACCTTTTATGACTACCAAGCCATGTGTAGAGCCAACAAGGAAAGCAGC  
 GATGGCGCCCATGGCCTCCTGGATCCTTATAATGCCTTCTCTGAGTAAATGGATCA  
 TGACAGAACTTGTCTTGTTCCTGGTGAATTTAACCTCTGCAGTTGGTGGCACTCCGATAT  
 GACAGCTAAAGCCCAGAAATTGAAACAGACCCTGGAGCCTTGTGATACTGAATATCCAGCA  
 TTCGTCTCTGAGCGCACCATCAAGGAGACTACAGGGAATATTGCTTGTGAAGACTGCTCCA  
 15 AGTCCTTTGTATCCAGCAAATCCCAAGCAGCAACCTGTTTATGGTGGTGGTGGACAGCAG  
 CTGCCTCTGTGAATCTGTGGCCCCCATCACCATGGCACCATTGAAATCAGGTATAATGAA  
 TCCCTTAAAGTGTGAACGTCTAAAGGCCAGAGATCAGAAGGCGCCAGAAATCTTGTATG  
 GCTTCCATCCTGAGGAGAATGCAAGGGAGTGTGGGGGTGCGCCGAGTCTCCAAGCCCAGAC  
 AGTCCTCCTTCTGCTCCCTCTGCTTTTGTATGCTCTTCTCAAGGTGACACTGACTGAGATGT  
 20 TCTCTTACTGACTGAGATGTTCTCTTGGCATGCTAAATCATGGATAAACTGTGAACCAAAA  
 TATGGTGCAACATACGAGACATGAATATAGTCCAACCATCAGCATCTCATCATGATTTTAA  
 ACTGTGCGTGATATAAACTCTTAAAGATATGTTGACAAAAAGTTATCTATCATCTTTTAC  
 TTTGCCAGTCATGCAAATGTGAGTTTGCCACATGATAATCACCTTCATCAGAAATGGGAC  
 CGCAAGTGGTAGGCAGTGTCCCTTCTGCTTGAACCTATTGAAACCAATTTAAACTGTGT  
 25 ACTTTTTTAAATAAAGTATATTAAAATCATAAAAAAAAAAAAAAAAAAAAA

## 22 - human alpha2 delta-3 amino acid sequence

MAGPGSPRRASRGASALLAAALLYAALGDVVRSEQQIPLSVVKLWASAFGGEIKSIAAKYS  
 GSQLLQKKYKEYEKDVAIEEIDGLQLVKKLAKNMEEMFHKKEAVRRLVEAAEEAHLKHEF  
 30 DADLQYEFNAVLINERDKDGNFLELGKEFILAPNDHFNNLPVNIISLSDVQVPTNMYNKDP  
 AIVNGVYWSESLNKFVVDNFDRDPSLIWQYFGSAKGFFRQYPGIKWEPDENGVIADFRCNR  
 KWIQAATS PKDVVILVDVSGSMKGLRLTI AKQTVSS ILDTLGDDDDFFNIIAYNEELHYVE  
 PCLNGTLVQADRTNKEHFREHLDKLFAKGIGMLDIALNEAFNILSDFNHTGQGSICSQAIM  
 LITDGAVDTYDTIFAKYNWPDRKVRIFTYLIGREAAAFADNLKWMACANKGFFTQISTLADV  
 35 QENVMEYLHVLSRPKVIDQEHVDVWTEAYIDSTLTDDQGPVLMTTVAMPVFSKQNETRSKG  
 ILLGVVGTDPVKELLKTI PKYKLGIGHYAFAITNNGYILTHPELRLLYEKGKRRKPNYS  
 SVDLSEVEWEDRDDVLRNAMVNRKTGKFSMEVKKTVDKGKRVLMVMTNDYYYTDIKGTPFSL  
 GVALSRGHGKYFFRGNVTIEEGLHDLEHPDVSLADEWSYCNTDLHPEHRHLSQLEAIKLYL

KGKEPLLQCDKELIQEVLFDVVSAPIEAYWTSALNKSSENSDKGVEVAFLGTRTGLSRIN  
 LFVGAEQLTNQDFLKAGDKENIFNADHFPLWYRRAAEQIPGSFVYSIPFSTGPNKSNVVT  
 ASTSIQLLDERKSPVVAAVGIQMKLEFFQRKFWTASRQCASLDGKCSISCDDETVCYLID  
 NNGFILVSEDTQTGDFGEIEGAVMNKLLTMGSFKRITLYDYQAMCRANKESSDGAHGLL  
 5 DPYNAFLSAVKWIMTELVLFLVEFNLCSSWWHSDMTAKAQKLKQTLPCDTEYPAFVSERTI  
 KETTGNIACEDCSKSFVIQIPSSNLFMVVDSSCLCESVAPITMAPIEIRYNESLKCERL  
 KAQKIRRRPESCHGFHPEENARECGGAPSLQAQTVLLLLPLLLMLFSR

### 23 - human amino acid sequence

10 MAVPARTCGASRPGPARTARPWPGCGPHPGPGTRRPTSGPPRPLWLLLPLLPLLAAPGASA  
 YSFPQQHTMQHWARRLEQEVGDVMRIFGGVQQLREIYKDNRNLFVQENEPQKLVEKVAGD  
 IESLLDRKVQALKRLADAAENFQKAHRWQDNIKEEDIVYYDAKADAELDDPESEDVERGSK  
 ASTLRDLDFIEDPNFKNKVNYSYAAVQIPTDIYKGSTVILNELNWTEALENVFMENRRQDPT  
 LLWQVFGSATGVTRYYPATPWRAPKKIDLYDVRRRPWYIQGASSPKDMV I IVDVSGSVSGL  
 15 TLKLMKTSVCEMLDLSDDDYVNVASFNEKAQPVSCFTHLVQANVRNKKVFKEAVQGMVAK  
 GTTGKAGFEYAFDQLQNSNITRANCNMIMMFTDGGEDRVQDVFEKYNWPNRTRVFTFS  
 VGQHNYDVTPLQWMACANKGYIFEIPSIGAIRINTQEYLDVLGRPMVLAGEAKQVQWNTV  
 YEDALGLGLVVTGTLPVFNLTQDGPGEKKNQLILGVMGIDVALNDIKRLTPNYTLGANGYV  
 FAIDLNGYVLLHPNLKPQTTNFREPVTLDFLDAELEDENKEEIRRSMDGNKGHKQIRTLV  
 20 KSLDERYIDEVTRNYTWVPIRSTNYSGLVLPYSTFYLQANLSDQILQVKYFEFLLPSSF  
 ESEGHVFIAPREYCKDLNASDNNTFLKNFIELMEKVTPDSKQCNNFLLHNLILDTGITQQ  
 LVERVWRDQLNTYSLLAVFAATDGGITRVFPNKAEDWTENPEPFNASFYRRSLDNHGYV  
 FKPPHQDALLRPLELENDTVGILVSTAVELSLGRRTLRAVVGVKLDLEAWAEKFKVLASN  
 RTHQDQPQKCGPNSHCEMDCEVNNEDELLCVLIDDGGFLVLSNQNHQWDQVGRFFSEVDANL  
 25 MLALYNNSFYTRKESYDYQAACAPQPPGNLGAAPRGVFVPTVADFLNLAWWTSAAAWSLFQ  
 QLLYGLIYHSWFQADPAEAGSPETRESSCVMKQTQYYFGSVNASYNAIIDCGNCSRLFHA  
 QRLTNTNLLFVVAEKPLCSQCEAGRLQKETHCPADGPEQCELVQRPRYRRGPHICFDYNA  
 TEDTSDCGRGAHHHHHH

### 30 24- mouse amino acid sequence

MAGPGSLCCASRGASALLATALYAALGDVVRSEQQIPLSVVKLWASAFGGEIKSIAAKYS  
 GSQLLQKKYKEYEKDVAIEEIDGLQLVKKLAKIMEEMFHKKSEAVRRLVEAAEEAHLKHEF  
 DADLQYEFYFNAVLINERDKDGNFLELGKEFILAPNDHFNNLPVNISLSDVQVPTNMYNKDP  
 AIVNGVYWSESLNKVFVDNFDRLPSLIWQYFGSAKGFFRQYPGIKWEPDENGVIADFCDNR  
 35 KWIQAATSPKDVVILVDVSGSMKGLRLTIKQTVSSILDTLGDDDDFFNIITYNEELHYVE  
 PCLNGTLVQADRTNKEHFREHLDKLFAKGIGMLDIALNEAFNILSDFNHTGQGSICSQAIM  
 LITDGAVDTYDTIFAKYNWPDRKVRIFTYLIGREAAFDNLKWMACANKGFFTQISTLADV  
 QENVMEYLHVLSRPKVIDQEHVWTEAYIDSTLPQAQKLADDQGLVLMTTVAMPVFSKQN

059760-05526300



	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
0	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

15 26 - nucleotide sequence

TCGGAATTCCTCAGTGATGGTGATGGTGATGGGCCCCGCGGCCACAGTC

## 20

28 - nucleotide sequence

TCTCAGTGATGGTGATGGTGATGCGATGCACCCCACACTCTC